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Milk protein is the most valuable milk component for which dairy producers 
receive payment. Despite its high value, altering milk protein composition and 
production in dairy cows by diet has been challenging, particularly as compared to 
altering milk fat. Improving the effi ciency of conversion of dietary nitrogen into 
productive nitrogen (as milk protein) has both fi nancial and environmental benefi ts to 
the dairy industry. Dietary strategies to improve milk protein yield have focused on 
amino acid requirements, metabolizable protein, and the interaction between dietary 
energy and protein. However, dietary interventions have had only moderate success in 
improving milk protein production in well-fed dairy cows.
Use of long-term hyperinsulinemic-euglycemic clamps in lactating cows has 
suggested that milk protein synthesis in dairy cows is not maximized under normal 
management conditions, as signifi cant improvements in milk protein have been 
observed in this experimental context. The goal of the present research was to expand 
on these observations by administering slow-release insulins, from human medicine, 
to lactating dairy cows. The hypothesis was that administration of slow-release 
insulins, without provision of supplemental glucose, would increase milk protein 
production and alter mammary metabolism in lactating dairy cows. 
In experiment one, two forms of slow-release insulin were tested in a dose 
response study. Both Humulin-N (H) and insulin glargine (L) exerted insulin-like 
effects in lactating dairy cows, evidenced by linear decreases of plasma glucose with 
increasing dose of slow-release insulin. In experiment two, H and L were given twice 
daily for 10 days to evaluate their effects on milk component production. Milk fat and 
protein content were both increased by treatment with H and L, suggesting that these 
forms of slow-release insulin alter metabolism and milk component synthesis. In 
experiment three, L was used in a mammary metabolism study to examine its effects 
on mammary uptake and utilization of substrates for protein synthesis. Reduced 
uptake of both essential and nonessential amino acids was observed during treatment 
with L, while milk protein yield remained the same for the control and treatment 
periods. This suggests that L alters metabolism and increases amino acid effi ciency of 
use within the cow.
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1CHAPTER ONE: INTRODUCTION
Protein is the most valuable milk constituent in multiple-component pricing 
systems, receiving the largest dollar per unit price of all the milk components. At the 
end of 2009, milk protein was valued at $6.35/kg ($2.88/lb), compared to $3.42/kg 
($1.55/lb) for milk fat. Though protein prices have come down from the highs in 2009, 
demand for milk protein still appears to be strong as per capita cheese consumption 
has shown steady growth over the last 20 years, with an average annual consumption 
of more than 71 kg of cheese per capita in 2008. The fi nancial incentive for milk with 
higher protein content, as well as the growing consumer demand for milk protein 
highlights the need to gain a greater understanding of nitrogen (N) effi ciency within 
the lactating dairy cow and how milk protein is synthesized within the mammary 
gland from available substrates.
The effi ciency of converting dietary crude protein into milk protein output in 
the lactating ruminant commonly ranges from 25 to 30 percent (Bequette et al., 1998). 
The conversion of metabolizable protein into true milk protein is about 0.62 to 0.64 
g of true milk protein per g of metabolizable protein (Metcalf et al., 2008). These 
levels of effi ciency, particularly in light of rumen N loss, also represent an area of 
opportunity for the dairy industry. Improving N effi ciency within the cow and across 
the rumen will help the industry to avoid costly N loss to the environment, as low N 
effi ciency of use leads to greater losses of N in urine (Broderick, 2003). The release 
of other pollutants to the environment from dairy cows such as ammonia can also be 
reduced by improving the N economy of the lactating cow (Frank et al., 2002).
The following review of the literature will describe strategies to alter milk 
protein composition in lactating dairy cows. From feeding and dietary strategies to 
regulation of protein synthesis at the cellular level, there appears to be opportunity to 
increase milk protein yield in the modern dairy cow.
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3CHAPTER TWO: REVIEW OF THE LITERATURE
DIETARY STRATEGIES TO INCREASE MILK PROTEIN YIELD
Improving milk protein production in the lactating dairy cow has been a 
challenge facing dairy producers, nutritionists, and dairy scientists for many years. 
Though milk fat can easily be manipulated by dietary intervention, milk protein 
has proven to be more challenging to alter in well-fed dairy cows. From a rumen 
perspective, lactating dairy cows are rather ineffi cient at converting dietary crude 
protein into productive N (Bequette et al., 1998), but are more effi cient at converting 
metabolizable protein into milk protein (Metcalf et al., 2008). Dietary strategies to 
increase milk protein production in lactating dairy cows have focused on increasing the 
metabolizable protein available to the cow, exploring the amino acid requirements for 
milk production, and investigating the interaction of protein and energy supply on milk 
protein yield. The following discussion will briefl y look at amino acid utilization by the 
mammary gland and then will expand with further information on dietary strategies to 
meet the amino acid needs of the mammary gland for milk protein synthesis.
Amino acid utilization by the mammary gland
The amount of amino acids available in the arterial blood supply to the 
mammary gland is dictated by splanchnic release, which is dependent on absorption 
from the gut and use of amino acids by the portal-drained viscera and liver. Though the 
utilization of amino acids by the mammary gland may be more or less related to diets 
and rations, the supply of amino acids to the mammary gland is certainly dependent 
on diet, absorption of amino acids by the gut, and catabolism and transfer of absorbed 
amino acids across the portal-drained viscera (Lapierre et al., 2006; Pacheco et al., 
2006). Therefore, amino acid use by the mammary gland will be briefl y discussed here 
before more in-depth discussion about dietary strategies to improve milk protein yield.
4When considering uptake and utilization of amino acids by the mammary 
gland, amino acids are generally divided into three groups based on the ratio of 
uptake from the blood to output in milk proteins (Mepham, 1982). Group 1 consists 
of essential amino acids that exhibit stoichiometric transfer from blood to milk protein 
and includes methionine, histidine, phenylalanine, tyrosine, and tryptophan. Group 
2 consists of the amino acids which are taken up from the blood in excess of the 
amount secreted in milk protein. Group 2 amino acids include arginine, lysine, and 
the branched-chain amino acids valine, leucine, and isoleucine. The Group 2 essential 
amino acids are used within the gland to supply N for synthesis of nonessential amino 
acids and are also used as sources of energy (Mepham, 1982). Also, these amino acids 
may also be used for regulation of protein synthesis and other metabolic processes 
(Escobar et al., 2006). Group 3 amino acids are taken up from the blood in quantities 
that are defi cient relative to their output in milk protein and broadly include the 
nonessential amino acids. 
Metabolizable protein supply
The supply of metabolizable protein available to the cow post-ruminally 
includes three components: ruminally-undegraded crude protein (RUP) originating 
from feeds, microbial protein synthesized in the rumen, and endogenous crude protein. 
According to the NRC (2001), “The goals of ruminant protein nutrition are to provide 
adequate amounts of rumen-degradable protein for optimal rumen effi ciency and 
to obtain the desired animal productivity with a minimum amount of dietary crude 
protein.” Thus, it becomes necessary to monitor degraded and undegraded protein in 
the rumen to predict and optimize cow performance.
In lactating dairy cows, improving the supply of metabolizable protein post-
ruminally by increasing the supply of RUP has increased milk yield and milk protein 
yield in a number of studies (Blouin et al., 2002; Noftsger and St Pierre, 2003; Raggio 
5et al., 2004; Weiss et al., 2009a). However, in some cases, the improvements in milk 
yield and milk protein yield under conditions of excess metabolizable protein supply 
result in reduced effi ciency of transfer of feed N and amino acids into milk (Raggio et 
al., 2004; Weiss et al., 2009b).
Microbial protein, synthesized in the rumen, is a major supply of metabolizable 
protein and amino acids to the lactating dairy cow (Clark et al., 1992). When high 
quality forages are fed, the contribution of microbial protein to the metabolizable 
protein pool may be 50 to 55% of the cow’s requirement (Chalupa and Sniffen, 2010). 
The amount of predicted metabolizable protein arising from microbial protein sources 
decreases when poor quality forages and silages are fed (Chalupa and Sniffen, 2010). 
In addition to overall forage quality, rumen microbial growth is dependent on the 
supply of ruminally-fermentable carbohydrate. Therefore, the end-products of rumen 
protein metabolism and passage of microbial protein to the duodenum are infl uenced 
by the source, degradability, and availability of carbohydrate supplies. Increasing 
the amount of grain in the diet can increase passage of microbial N to the duodenum 
(Oba and Allen, 2003). Suffi cient fermentable carbohydrate available to the rumen 
microbial population is necessary to prevent losses of N as ammonia (Firkins et al., 
2007). As microbial protein supplies a signifi cant portion of protein available in the 
small intestine, predicting the passage quantity and quality of ruminally-synthesized 
microbial protein is of signifi cant importance. 
In practice, predicting microbial protein fl ow to the duodenum has not been 
simple and numerous approaches and models have been used to help gain a greater 
understanding of microbial protein fl ow out of the rumen (Firkins et al., 2006). Crude 
protein and ruminally-available protein supplied in the cow’s diet serve as the N 
supplies for rumen microorganisms; therefore, it is important to have suffi cient N 
available in the rumen for use by the microbes. The amino acid profi le of microbial 
protein is thought to be relatively constant (Clark et al., 1992). The conversion of 
6microbial protein to metabolizable protein is around 64% (National Research Council, 
2001; Metcalf et al., 2008). 
Endogenous protein fl ow into the small intestine consists of scurf proteins 
and sloughed epithelial cells. Endogenous protein certainly contributes to the 
metabolizable protein pool in the small intestine and the Dairy NRC (2001) estimated 
that endogenous protein supplies about 5% of total protein to the cow. In a more recent 
review, researchers estimated the fl ow of free endogenous protein to the duodenum 
to be 13% (Marini et al., 2008). Though endogenous protein contributes to the 
metabolizable protein pool available to the cow as N, further discussion is beyond the 
scope of this review.
Amino acid nutrition
Research in dietary strategies to improve milk protein production has shifted 
from focusing on dietary crude protein concentrations to looking at amino acid supply 
and metabolizable protein that are available to the cow post-ruminally. As amino acids 
are the actual building blocks for protein synthesis, numerous research groups have 
attempted to determine amino acid requirements and limiting amino acids for milk 
protein synthesis in lactating dairy cows. Compared with monogastrics, determining 
the amino acid requirements of ruminants is much more complicated due to the effects 
of rumen fermentation and microbial protein supply. 
Recent research has confi rmed that, as a group, essential amino acids are 
indeed essential when metabolizable protein supplies are limiting (Doepel and 
Lapierre, 2010) and the mammary gland adjusts blood fl ow and uptake of amino acids 
under defi cient conditions (Cant et al., 2001). Of the essential amino acids, lysine and 
methionine have been identifi ed as the most limiting amino acids in lactating dairy 
cows (e.g. Schwab et al., 1976; National Research Council, 2001). Lysine appears to 
be either the fi rst or co-limiting amino acid in early and at peak lactation (Schwab et 
7al., 1992a), whereas the status of methionine as the second-most limiting amino acid in 
that study was more variable. Determining the next most limiting amino acids beyond 
lysine and methionine has been less consistent, but phenylalanine (Nichols et al., 
1998), valine (Broderick et al., 1974), histidine (Vanhatalo et al., 1999), and arginine 
(Mepham, 1982) may be limiting under varying dietary conditions. 
A number of studies have been carried out to determine requirements for 
lysine and methionine in cows fed corn-based diets, and according to the NRC (2001) 
it was recommended that lysine contribute between 7 and 7.3% of metabolizable 
protein and that methionine contribute about 2.5% of metabolizable protein in diets 
for milk protein yield to be maximized (e.g. Schwab et al., 1992a; Schwab et al., 
1992b; Rulquin et al., 1993; Pisulewski et al., 1996). In 2009, Schwab and coworkers 
reevaluated the breakpoint estimates reported in the NRC (2001) and found that 
for maximal milk protein content, lysine and methionine should comprise 6.80 and 
2.29% of metabolizable protein, respectively. For maximal milk protein yield, the 
reevaluated lysine and methionine recommendations were more similar to the original 
NRC recommendations, consisting of 7.10 and 2.52% of metabolizable protein as 
lysine and methionine, respectively (Schwab et al., 2009). These recommendations 
may vary slightly depending on which ration balancing model is used, as slightly 
different approaches to predicting post-ruminal amino acid supplies in the models 
cause differences in the estimates for maximal yield of milk protein (Pacheco et al., 
2006; Schwab and Foster, 2009; Whitehouse et al., 2009). The breakpoint estimates 
for optimal ratios of lysine to methionine in metabolizable protein for maximal milk 
protein yield are 2.82, 3.00, and 2.92 for the NRC (2001), CPM-Dairy (v.3.0.10), and 
AMTS.Cattle (v.2.1) models, respectively (Schwab et al., 2009).
Both lysine and methionine are commercially available in rumen-protected 
forms for use in dairy cattle rations. When diets are defi cient in methionine, rumen-
protected methionine can meet the methionine needs of the cow and improve 
8production (Patton, 2010). While other amino acids are not commercially available 
in rumen-protected form, the technology to protect amino acids from rumen 
degradation yet still allow digestion in the small intestine is available. Other rumen-
protected amino acids have been used in research, such as rumen-protected arginine 
(Kirchgessner et al., 1993), though no positive effects of the arginine on milk 
production were observed in that study.
In a review by Firkins et al. (2006), the authors draw attention to the large 
variation associated with post-absorptive metabolism and the variation of success 
with either rumen-protected amino acids or increased dietary RUP. This variation, in 
combination with not having a full understanding of the amino acid requirements of 
the lactating dairy cow continue to provide challenges to scientists, dairy producers, 
and nutritionists in fi ne-tuning dairy cow rations.
The interaction of dietary protein and energy on milk protein
Dietary protein and energy concentrations have been extensively studied in 
an effort to improve milk protein production in lactating cows and have been the 
subject a number reviews (e.g. Sutton, 1989; Coulon and Remond, 1991). When 
either metabolizable protein or metabolizable energy are limiting, milk production 
and protein yield cannot be maximized. On the other hand, when either protein or 
energy are fed in excess, effi ciency of use and conversion to milk energy is reduced, 
suggesting a point of marginal return in feeding energy and protein.
In a study by Broderick (2003), cows were fed increasing amounts of crude 
protein and increased amounts of dietary energy (through a reduction in dietary neutral 
detergent fi ber [NDF]) in a large Latin square experimental design. There were no 
interactions between dietary crude protein and energy content for milk yield or milk 
protein yield, and the effects of increased crude protein in the diet on milk production 
were minimal. Cows fed higher crude protein diets had a signifi cant and large decrease 
9in N effi ciency as evidenced by large increases in milk urea and nonprotein N (NPN) 
and increased urinary N excretion. On the other hand, increasing the dietary energy 
concentration resulted in positive increases in milk yield and component yield while 
improving N effi ciency and reducing milk NPN, urea N, and urinary N excretion.
In a study evaluating the interaction of energy and metabolizable protein in 
the diet, Rius et al. (2010b) also reported no interactions between diet energy and 
metabolizable protein concentration on milk yield or milk protein yield. Metcalf et al. 
(2008) suggested that metabolizable energy will only improve milk production when 
there is suffi cient metabolizable protein; therefore, if metabolizable protein is limiting, 
additional metabolizable energy will not improve milk yield.
Other research has shown an interaction between dietary energy and protein 
on milk production and composition. Diets with low protein to energy ratios resulted 
in lower blood urea concentrations than diets with high protein to energy ratios (Brun-
Lafl eur et al., 2010). In that study, milk and protein yields increased more when 
dietary energy supply was increased in a high protein diet than in a diet designed to 
meet protein requirements. As alluded to in the previous paragraph, milk production 
and responses to either energy or protein are dependent on whichever nutrient is more 
limiting for production (Tedeschi et al., 2006).
Summary of dietary strategies to improve milk protein production
The Dairy NRC (2001) summarized available information regarding dietary 
infl uences on milk protein content and yield, with primary focus on modulation of 
milk protein through amino acid supplementation. In general, the opportunity to 
increase milk protein content and yield through known dietary strategies appears 
to be less than 5% per day. Though this review has only briefl y discussed some of 
the dietary strategies to improve milk protein yield, it is likely that conventional 
approaches to increase milk protein will have modest success in well-fed dairy cows. 
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ALTERNATIVE STRATEGIES TO INCREASE MILK PROTEIN YIELD
Most of the protein and amino acid requirements discussed in the NRC (2001) 
and the research discussed above has focused on metabolizable protein and amino 
acids in the context of substrate supply for mammary milk protein synthesis. However 
a paradigm shift is occurring in dairy cattle research, and amino acids and energy 
supply are being investigated as regulators of the overall process of protein synthesis 
in addition to being used as substrates for the proteins themselves (Moshel et al., 2006; 
Toerien et al., 2010; Rius et al., 2010a). Focus on the regulation of protein synthesis 
may provide more information about how nutrients are used in the lactating cow 
mammary gland to synthesize the casein and whey proteins. 
In addition to regulation of protein synthesis by nutrient supply, hormone 
signaling pathways can directly and indirectly affect the process of milk and milk 
protein synthesis, including the pathways of growth hormone (Hayashi et al., 2009), 
insulin (e.g. Park et al., 1979; Choi et al., 1988; Choi et al., 2004), prolactin (Choi 
et al., 1988; e.g. Choi et al., 2004), thyroid hormones (Miller and Swanson, 1969), 
insulin-like growth factor-I (IGF-I) (Cohick, 1998), steroid hormones, and leptin 
(Feuermann et al., 2008). 
Insulin may be of key importance in milk protein synthesis because of its role 
in global protein synthesis and translation (rev. by Proud, 2006; Proud, 2007). Menzies 
(2009) investigated the role of insulin in mRNA expression of the major milk protein 
genes by culturing mammary explants with one of three treatments: no hormones, 
hydrocortisone and prolactin, and insulin, hydrocortisone, and prolactin. Maximal 
mRNA expression of α-S1 casein, α-S2 casein, β-casein, κ-casein, α-lactalbumin, 
and β-lactoglobulin, was observed with the culture that included insulin. Insulin also 
stimulates the release and secretion of proteins from mammary acini (Park et al., 1979).
Additionally, insulin and energy status (Campbell et al., 1999), and amino 
acids (Beugnet et al., 2003) are known to interact with and infl uence the mammalian 
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target of rapamycin (mTOR) signaling pathway (Wang et al., 2005). Microarray data 
from mammary explant work by Menzies et al. (2009) suggest that insulin stimulates 
mRNA expression of 28 genes directly related to protein synthesis and protein 
synthetic machinery. More detailed discussion of mTOR signaling and regulation of 
translational processes will follow.
There is evidence in lactating cows to support the hypothesis that insulin 
stimulates milk protein synthesis. Work with hyperinsulinemic-euglycemic clamps to 
study the effects of insulin in lactating dairy cows has shown signifi cant increases in 
milk protein content and yield (McGuire et al., 1995; Griinari et al., 1997a; Mackle et 
al., 1999; Mackle et al., 2000). From this point forward, this review will focus on the 
role of insulin in milk protein synthesis, regulation of protein synthesis and translation, 
and potential methods to study the effect of insulin without provision of exogenous 
glucose supplies.
Hyperinsulinemic-euglycemic clamps
The use of hyperinsulinemic-euglycemic clamps in experimental contexts 
has been useful over the last 30 years as an in vivo model to examine whole body 
insulin response or action. First described in human subjects (DeFronzo et al., 1979), 
the concept of increasing circulating insulin concentrations by a constant insulin 
infusion rate with coinciding glucose infusion at a varied rate to maintain euglycemia 
has become the gold standard method for examining tissue insulin sensitivity. 
Hyperinsulinemic-euglycemic clamps have also been used to study the effects of 
insulin without the confounding effect of lowered glycemia or severe hypoglycemia.
The use of hyperinsulinemic-euglycemic clamps in animal experiments has 
grown over time, and one of the fi rst experiments in large cattle was described by 
Sano et al., (1991) in which the clamp was used on lactating, late pregnant, and non-
pregnant, non-lactating Japanese Shorthorn (beef) cows. During the short, two-hour 
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clamp period, a higher glucose infusion rate was required in lactating cows to maintain 
euglycemia as compared to non-lactating, late pregnant cows, suggesting differences 
in glucose uptake based on physiological state. Additionally, plateau insulin 
concentrations during infusion were lower in lactating and non-lactating, late pregnant 
cows compared to non-lactating, non-pregnant cows, indicating altered insulin uptake 
and utilization by physiological state. 
With long-term hyperinsulinemic-euglycemic clamps carried out over days, 
rather than hours, numerous studies have shown increased milk protein content 
and yield in lactating dairy cows. With shorter duration of the hyperinsulinemic-
euglycemic clamp (hours), changes in milk protein output have not been observed. 
An example of the plasma insulin and blood glucose concentrations observed during a 
hyperinsulinemic-euglycemic clamp in lactating cows is shown in Figure 2-1. 
Figure 2-1. Plasma insulin, blood glucose, and glucose infusion rate during a 
hyperinsulinemic-euglycemic clamp from Mackle et al. (1999). A constant infusion 
of insulin into jugular catheters was maintained for 4 d at a rate of 1 mg/kg of BW 
per hour. A 50% dextrose solution was co-infused with the insulin to maintain blood 
glucose concentrations within 10% of baseline concentration measurements taken 
before the start of the infusions.
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In lactating dairy cows, one of the fi rst experiments using the 
hyperinsulinemic-euglycemic clamp technique was carried out to evaluate the 
effect of insulin on milk synthesis (McGuire et al., 1995b) and components of 
the IGF system (McGuire et al., 1995a). During the 4-d clamp period in which 
circulating insulin concentrations were elevated more than fi ve-fold above baseline 
concentrations, McGuire and coworkers observed a 0.07 kg/d increase in milk protein 
yield, representing a 7% increase in milk protein output during the clamp period. In 
a subsequent experiment from the same group at Cornell University, Griinari et al., 
(1997a; 1997b) used the clamp technique in mid-lactation cows to elevate circulating 
insulin concentrations four-fold above baseline in conjunction with abomasal infusion 
of casein. During the clamp and abomasal infusion, milk protein yield was increased 
0.23 kg/d or 28% above baseline production. With provision of additional protein 
substrate in the abomasum in the form of casein and amino acids, (Mackle et al., 
1999) observed a 25% increase in milk protein output under hyperinsulinemic-
euglycemic clamp conditions accompanied by a decrease in circulating essential 
amino acid concentrations, increased mammary blood fl ow, increased extraction 
effi ciency of amino acids, and increased glucose uptake (Mackle et al., 2000). These 
results suggest that maximal milk protein production by the mammary gland has not 
been fully reached with common lactating rations. Additionally, it appears that the 
hyperinsulinemic-euglycemic clamp alters mammary gland uptake and metabolism of 
protein substrates.
Laarveld and coworkers (1981) used a co-infusion of insulin and glucose (not 
necessarily a hyperinsulinemic-euglycemic clamp, per se) to evaluate the effect of 
insulin on mammary arteriovenous differences in amino acids and metabolites across 
the mammary gland. They observed modest (10 to 20%) increases in uptake of some 
amino acids by the mammary gland with insulin treatment and increased extraction of 
aspartate, isoleucine, and leucine from the plasma.
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The changes in milk protein content and yield observed under long-term 
hyperinsulinemic-euglycemic clamps provide insight into the hormonal regulation 
of mammary metabolism and protein synthesis. While the elevation of insulin often 
receives the credit for the change in milk protein content and yield (Griinari et al., 
1997a; Mackle et al., 1999), the confounding effect of glucose infusion cannot be 
ignored. 
One of the reasons the co-infusion of glucose during hyperinsulinemic-
euglycemic clamps cannot be ignored in interpreting results is because of the 
substantial amount of energy that glucose provides to the cow during the clamp period. 
In the study by Mackle et al., (1999) the amount of glucose infused per day (3.336 
kg) was the equivalent of 12.2 Mcal NEL/d (Leonard and Block, 1997) which is a 
considerable amount of energy. As energy supply to the cow by diet exerts effects on 
milk protein content and yield (Broderick, 2003), the additional energy supply to the 
cow provided by infused glucose during hyperinsulinemic-euglycemic clamps may 
also be infl uencing mammary milk protein synthetic machinery.
Metcalf and coworkers (1991) attempted to carry out a close arterial infusion 
of insulin by infusing insulin directly into the external pudic artery on both sides of 
the mammary gland. The close arterial infusion of insulin resulted in a 36% increase 
in arterial plasma insulin concentrations. However, there was no change in arterial 
plasma glucose concentrations in this study, leading the authors to conclude that close 
arterial infusion of insulin in the mammary gland did not elevate systemic insulin 
concentrations. Large variation in blood fl ow complicated the results for this research 
group, and no changes in milk protein content were observed. This study is, however, 
an interesting approach to study the effect of insulin without co-infusing glucose.
The link between glucose, insulin, and milk protein production is also observed 
during glucose infusions. Amaral et al., (1990) observed a 10.5% increase in milk 
protein yield when cows were infused intravenously infused with 737 g/d of glucose. 
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A trend for higher plasma insulin in cows treated with intravenous (i.v.) glucose 
was observed in this study (P = 0.12, 499 vs. 634 pg/ml for control vs. i.v. glucose). 
Additionally, Rulquin et al., (2004) reported a quadratic increase in milk protein yield 
with duodenal glucose infusions, and this was associated with numerically higher 
arterial insulin concentrations. This study also showed that infusion of glucose caused 
the mammary gland to extract more essential amino acids than other treatments.
TRANSLATION AND PROTEIN SYNTHESIS
To understand how milk proteins are synthesized, it is useful to understand the 
basic process of mRNA translation and global protein synthesis. Eukaryotic protein 
synthesis and regulation of translation is fairly well understood and the subject is 
covered in numerous reviews (e.g. Rhoads, 1999; Jackson et al., 2010) and textbooks 
(e.g. Lodish et al., 2004). Recent research in dairy cows and bovine cell lines 
indicates that translation is a critical step in regulation of milk protein synthesis and is 
infl uenced by lactogenic hormones and amino acids (Toerien and Cant, 2007; Hayashi 
et al., 2009; Burgos et al., 2010). The three basic steps of mRNA translation which 
include initiation, elongation, and termination, will be discussed in the following 
section, along with the regulation of those steps by intracellular signaling cascades.
Translation initiation
The entire translation process is principally regulated at the initiation step 
(Jackson et al., 2010). Initiation is the most complex stage of translation and involves 
numerous protein-protein interactions and exchanges. Assembly of the ribosome 
occurs during initiation and is necessary for translation to begin. The ribosome 
consists of large and small ribosomal subunits, the 60S and 40S subunits. When the 
ribosomal subunits are not actively participating in translation, they are bound and 
kept apart by two initiation factors (IF), named eIF3 and eIF6 (Illustration 2-1).
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Illustration 2-1. Simplified illustration of ribosome assembly adapted from Lodish et 
al (2004). The 80S ribosome, after completing a round of translation, dissociates into 
the 60S and 40S subunits which re-associate with their initiation factors, eIF6 and 
eIF3, respectively. These complexes are then recycled to undergo another round of 
translation.
For the 40S ribosomal subunit to bind to the 60S subunit, a preinitiation 
complex must be formed between the 40S-eIF3 complex, another initiation factor, 
eIF1A, and a ternary complex consisting of an additional initiation factor (eIF2) 
which is bound with GTP and a methionine-charged tRNA (methionyl tRNAiMet) 
(Illustration 2-2, Step 1). An important control point of translation initiation is the 
phosphorylation status of the eIF2 bound to GDP. If eIF2 is phosphorylated, the eIF2-
GDP complex cannot exchange bound GDP for GTP, inhibiting its ability to bind with 
the methionine-charged tRNA, which thus inhibits protein synthesis. 
The mRNA awaiting translation is capped at the 5’ end and is bound by an 
initiation factor, eIF4. The mRNA-eIF4 complex associates with the preinitiation 
complex (40S-eIF3-eIF1A-eIF2-GTP- methionyl tRNAiMet) and forms the initiation 
complex (Illustration 2-2, Step 2). The initiation complex scans the mRNA for the start 
codon. Upon reaching the start codon, the GTP associated with eIF2 is hydrolyzed 
(Illustration 2-2, Step 3), which is an irreversible step and prevents the initiation 
complex from any further scanning.
When the initiation complex reaches and associates with the start codon, the 
60S ribosomal subunit joins the initiation complex to form the 80S ribosome. Another 
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initiation factor, eIF5, which is associated with GTP, is required to release eIF6 from 
the 60S subunit and free it to join the 40S subunit. Hydrolysis of the GTP associated 
with eIF5 subsequently frees the 60S subunit to associate with the 40S subunit, 
completing formation of the 80S ribosome (Illustration 2-2, Step 4).
Illustration 2-2. Initiation of translation and 80S ribosome assembly adapted from 
Lodish et al. (2004). The individual steps referenced in the text are shown in this 
figure as black squares containing numbers. Steps 1 and 2 indicate formation of the 
preinitiation and initiation complex through addition of various initiation factors. Step 
3 illustrates the positioning of the 40S subunit after the initiation complex has scanned 
the mRNA for the start codon. Step 4 shows the release of initiation factors allowing 
the 60S subunit to join with the 40S subunit to form the 80S ribosome and start mRNA 
translation.
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Translation elongation
Upon correct positioning of the 80S ribosome, peptidyl chain elongation 
can begin. Another set of proteins is necessary for elongation to occur and these 
proteins are called elongation factors or EFs. Elongation of the peptidyl chain has 
three key steps: entry of amino acid-charged tRNAs, peptide bond formation, and 
the translocation of the ribosome complex along the mRNA one codon at a time. 
Each new amino acid to be added to the polypeptide chain is transported to the 80S 
ribosome complexed as an aminoacyl-tRNA associated with eEF1A-GTP. When the 
amino acid is correctly lined up with the mRNA codon, the GTP undergoes hydrolysis 
and results in the freeing of eEF1A-GDP from the tRNA and peptide bond formation 
in the growing polypeptide chain. Once the peptide bond is formed, the 80S ribosome 
must translocate down the mRNA. Translocation is promoted by the hydrolysis of 
eEF2-GTP to eEF2-GDP.
Translation termination
Upon reaching a stop codon on the mRNA strand, two release factors (RF) are 
involved in termination of translation and release of the ribosome from the mRNA. 
Release factor eRF1 and eRF3-GTP promote cleavage of the peptidyl-tRNA and 
release the completed protein. Following release, the protein is able to fold into its 
native conformation, which is facilitated by chaperone proteins.
Regulation of signaling pathways infl uencing protein translation
Translation is regulated by signaling pathways that affect phosphorylation 
status and GTP-GDP hydrolysis of the initiation, elongation, and termination factors. 
Many signaling pathways intersect and overlap to regulate these aforementioned 
translation factors. One of the major signaling pathways that infl uences protein 
translation is the mTOR signaling cascade.
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Regulation of translation initiation factors. As mentioned earlier, the 
phosphorylation status of eIF2 dictates whether or not translation can begin. If 
eIF2-GTP is phosphorylated, it can bind with the ternary complex and participate 
in translation initiation. However, if eIF2-GDP is phosphorylated, then translation 
initiation will not occur. Serine 51 is the amino acid residue on eIF2 that undergoes 
changes in phosphorylation status. Four mammalian kinases are known to 
phosphorylate eIF2a on Ser51 (Jackson et al., 2010).
The ability of eIF4 to interact with the mRNA is also affected by 
phosphorylation status. However, it is not direct phosphorylation of eIF4 that changes 
its ability to interact with the mRNA, rather, it is the phosphorylation status of 
binding proteins that interact with eIF4 that dictate its activity. As shown in the earlier 
Illustration 2-2, eIF4 is a multi-protein complex consisting of eIF4A, eIF4B, eIF4E, 
and eIF4G. Phosphorylation status of eIF4E binding proteins, also known as 4E-BPs, 
affects the association of eIF4E with the eIF4 complex. When hypo-phosphorylated, 
4E-BP is bound with eIF4E, making it unavailable for association with the eIF4 multi-
protein complex. On the other hand, when 4E-BP is hyper-phosphorylated, eIF4E 
is released and allowed to interact and associate with the eIF4 complex, allowing 
translation initiation to proceed. Hyper-phosphorylation of 4E-BP, also often referred 
to as 4E-BP1, is under the control of mTOR.
In addition to altered phosphorylation status of the initiation factors, the 
40S ribosome contains a subunit protein called ribosomal protein S6, or rpS6. This 
phosphorylation of this protein is carried out by S6 kinase 1 (S6K1). In addition to 
4E-BP1, S6K1 is the second main target for the kinase activity of mTOR. When 
S6K1 becomes hyper-phosphorylated, it becomes active and is able to phosphorylate 
target proteins, including rpS6. Phosphorylation of rpS6 is permissive to translation 
and its phosphorylation status is positively correlated with protein synthesis 
(Thomas et al., 1982).
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Regulation of translation elongation factors. Though initiation is highly 
controlled and very important in rates of translation, the elongation step is also subject 
to regulation and control by phosphorylation events (Browne and Proud, 2002). The 
two main elongation factors, eEF1 and eEF2, are targets for phosphorylation by 
different kinases. These kinases include protein kinase A (PKA), protein kinase C 
(PKC), and other kinases involved in cell cycle control. 
Phosphorylation of eEF2 can and does occur at various amino acids, and in 
general, phosphorylation inhibits its activity. A specifi c kinase for eEF2 was identifi ed 
1987 and this kinase is dependent on calcium and calmodulin (rev. by Browne and 
Proud, 2002) and is aptly named eEF2 kinase. At some amino acids of eEF2 kinase, 
phosphorylation activates the kinase, while at other amino acids, phosphorylation 
inhibits the kinase activity. These amino acid sites are acted on by numerous other 
kinases including S6K1, PKA, AMPK and others (Illustration 2-3). As S6K1 is 
phosphorylated by mTOR, it becomes active and is able to phosphorylate eEF2 kinase. 
This phosphorylation of eEF2 kinase inhibits its activity. If eEF2 kinase is inhibited, 
then its downstream target protein, eEF2, is not being phosphorylated. Therefore, a 
downregulation in the phosphorylation of eEF2 is permissive to translation elongation. 
Indeed, insulin decreases the activity of eEF2 kinase and insulin also causes a decrease 
in the phosphorylation status of eEF2, which allows it to participate in elongation 
(Redpath et al., 1996).
Illustration 2-3. Sites of phosphorylation changes on eEF2 kinase, adapted from a 
review by Proud (2007). White circles represent sites that when phosphorylated inhibit 
kinase activity whereas gray hexagons are sites, that when phosphorylated, activate 
eEF2 kinase activity. The phosphorylation of eEF2 kinase by S6K1 at Ser 366 is 
inhibitory and under control of mTOR signaling pathways. 
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Mammalian target of rapamycin signaling
The mammalian target of rapamycin, or mTOR, is a central mediator of 
cellular metabolism, cellular growth and apoptosis, and global protein synthesis 
(Yang et al., 2008). Numerous reviews have been published about mTOR and its 
role in these cellular processes (e.g. Proud, 2006; Proud, 2007; Yang et al., 2008). 
The mTOR signaling pathway is a crossroads for signaling cascades arising from 
various sources, including amino acids and insulin. Activation of the mTOR complex 
allows for downstream activation of proteins and kinases involved with the mRNA 
translation processes and proteins described earlier in this review. The mTOR 
complex contains multiple proteins including Ras homolog enriched in brain (Rheb, a 
GTP-GDP-bound protein), PRAS40, regulatory-associated protein of mTOR (raptor), 
and G protein β-subunit-like protein (GβL). 
Nutrient status and availability impacts cellular metabolism and mRNA 
translation by affecting phosphorylation status and activation of multiple translation 
factors (Campbell et al., 1999). Insulin, upon binding to its cell surface receptor, 
causes recruitment and activation (by way of insulin receptor substrate, IRS) of 
phosphatidylinositol 3’ kinase (PI3K). Upon activation, PI3K phosphorylates Akt 
at Thr 308 and Ser 473 (Zhang et al., 2009). When Akt is fully phosphorylated, 
it subsequently phosphorylates and inactivates the tuberous sclerosis complexes, 
TSC1 and TSC2. The tuberous sclerosis complexes inhibit mTOR activity. Once 
the repression of the TSC is removed by phosphorylation, mTOR enables the 
phosphorylation of 4E-BP1 and S6K1. Additionally, in vitro work has shown that 
PRAS40 is inhibitory to mTOR kinase activity, but phosphorylation of PRAS40 
removes the inhibition on mTOR (Sancak et al., 2007). PRAS40 is a target of Akt 
phosphorylation. As mentioned earlier, both 4E-BP1 and S6K1 are important in 
regulating steps during translation. Illustration 2-4 shows the basic steps involved in 
insulin signaling and its interaction with mTOR.
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Illustration 2-4. Insulin signal transduction pathway and its interaction with mTOR. 
Phosphorylation is represented in this illustration by encircled “P” and can represent 
phosphorylation at multiple amino acid sites. Insulin binds with its cell surface 
receptor resulting in recruitment and tyrosine phosphorylation of insulin receptor 
substrate (IRS). Phosphorylation of IRS results in activation of phosphatidylinositol 3’ 
kinase (PI3K) which phosphorylates and activates Akt. Akt has kinase activity, which 
phosphorylates the tuberous sclerosis complexes (TSC). The TSC proteins inhibit 
mTOR activity by way of Rheb and phosphorylation of TSC removes the inhibition 
from mTOR. When active, mTOR phosphorylates 4E-BP1 and S6K1. These final steps 
are permissive to mRNA protein translation. 
There is evidence that the mTOR signaling pathway is at work in the 
mammary gland of lactating dairy cows. The research groups at the University of 
Guelph and Virginia Polytechnic University, as well as a few other universities, 
have looked at various proteins and kinases involved in mTOR signaling specifi c to 
bovines. Phoshorylation of rpS6 is greater in the mammary gland of lactating cows 
than non-lactating cows (Toerien and Cant, 2007). The level of mRNA expression of 
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proteins linking insulin and mTOR signaling are also increased by lactation including 
Akt, mTOR, eIF4E, and S6K1 (Bionaz and Loor, 2007). Additionally, mammary 
explants incubated with a combination of leptin, prolactin, and insulin showed 
increased expression of mTOR (Feuermann et al., 2008). 
Burgos and Cant (2010) showed that global protein synthesis rates were 
increased by 47% in MAC-T cells treated with IGF-I. Responses to treatment of 
MAC-T cells with IGF-I included increased phosphorylation of Akt on Ser 473, a 
progressive increase in the phosphorylation state of S6K1, increased phosphorylation 
of 4E-BP1, and increased phosphorylation of TSC2. Additionally, in MAC-T cells, 
overexpression of eIF4E is associated with increased growth and proliferation of the 
cells (Long et al., 2001). All of the above responses correlate with higher translation 
and increased protein synthesis.
Toerien et al., (2010) used a feed deprivation-refeeding model in cows to 
study the effects of amino acids and glucose on protein synthesis. In this study, 
phosphorylation of S6K1 was higher for cows treated with essential AA and glucose 
compared to saline (control) cows. Additionally, the substrate for S6K1, rpS6, was 
also more phosphorylated for cows on this treatment compared to control cows. 
Though not statistically signifi cant, insulin concentrations over the 9-h infusion 
period were numerically 29% higher for the essential amino acid and glucose 
treatment versus control. This study would represent acute changes in the protein 
synthetic machinery. 
In research at Virginia Tech, abomasal starch infusion in intake-restricted cows 
increased circulating insulin concentrations (Rius et al., 2010a). In mammary tissue 
biopsies collected from these cows, there was an increased ratio of phosphorylated 
rpS6 to total rpS6 compared to control cows. These results suggest that insulin 
infl uences the mRNA translation process by altering phosphorylation status of kinases 
and proteins involved in protein synthesis.
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In low producing cows, treatment with long-acting growth hormone stimulated 
milk yield and milk protein yield and affected the mTOR signaling cascade (Hayashi 
et al., 2009). In that study, phosphorylation of rpS6 was greater for cows treated with 
growth hormone and total abundance of eIF4E and eEF2 were greater in growth 
hormone-treated cows.
All of the above studies in lactating cows or bovine cell lines indicate that the 
mTOR signaling pathway is active within the mammary gland. Methods to infl uence 
and upregulate mTOR signaling in lactating cows warrant further investigation as a 
way to alter mammary milk protein synthesis.
INSULIN AND INSULIN ANALOGUES
The discovery and partially successful isolation of insulin extracts in the 1920s 
by Banting and Best was a scientifi c breakthrough that almost single-handedly took 
away the lethality of diabetes, which at the time, had been an incurable, untreatable 
disease (Bliss, 1982). Through a transition from animal insulins to recombinantly-
made insulins, human diabetes has become a very treatable disease. Today, numerous 
insulins and insulin analogues are readily available for patients to use depending on 
type and severity of diabetes, time of day or timing of last meal, and other varying 
factors (Sheldon et al., 2009). Commercially available insulins and insulin analogues 
come in rapid-acting, intermediate-acting, and long-acting formulations.
An early form of insulin used in diabetes treatment included Neutral Protamine 
Hagedorn (NPH) insulin, which is a suspension of crystals of protaminated insulin. 
When combined with insulin in the suspension and injected into patients, the 
protamines slow the release of the insulin molecules into circulation. Introduced for 
commercial use in the 1940s, NPH is commonly classifi ed as an intermediate-acting 
insulin. In its early uses, NPH insulin was used to replace basal insulin secretion in 
diabetic patients by administration once or twice per day. The peak action of NPH 
25
insulin occurs 4 to 6 h after administration and effects can last between 12 and 16 h 
(rev. by Peterson, 2006).
One of the goals of insulin therapy is to reduce the risk of hypoglycemic 
episodes in patients while still maintaining good glycemic control. While NPH insulin 
was somewhat effective for overall glycemic control, there were still problems with 
hypoglycemic episodes. In an effort to obtain better control of glycemia, other insulin 
products with short or immediate action profi les were developed and introduced 
as mealtime insulins. Even with the development of mealtime insulins, there was 
still a need for better control of basal insulin concentrations. Eventually, a class of 
long-acting insulins were developed that provided better basal glycemic control and 
reduced the risk of hypoglycemic episodes. It should be noted, however, that although 
long-acting insulins are able to reduce the incidence of hypoglycemia, there is still 
considerable within-subject variability in response to insulin injection (Heinemann, 
2002) which is of concern when treating diabetic patients.
Insulin glargine is a recombinant, human insulin analogue and is classifi ed 
as a long-acting insulin, with up to 24 h in duration (Goykhman et al., 2009). 
Insulin glargine was approved for use in the United States by the Food and Drug 
Administration (FDA) in April 2000 and is sold under the trade name of “Lantus” by 
Sanofi -Aventis. Glargine differs from native human insulin with a glycine substitution 
for an asparagine residue at position A21 and addition of two arginine residues on the 
carboxy end of the B-chain at positions B31 and B32 (Bolli and Owens, 2000). The 
amino acid substitutions to this analogue shift the isoelectric point of the molecule 
from pH 5.4 to 6.8. The shift in the isoelectric point makes the analogue soluble in a 
more acidic solution than unaltered insulin, but when glargine is given subcutaneously, 
it precipitates at the more neutral pH of the injection site, slowly dissipating and being 
absorbed over a prolonged period of time. A comparison of the structures of human 
insulin, bovine insulin, and insulin glargine is depicted in Illustration 2-5.
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Illustration 2-5. Comparison of the structures of human insulin (A), bovine insulin (B), 
and insulin glargine (C). Gray circles represent amino acid differences between bovine 
insulin and human insulin or insulin glargine. Black circles represent the amino acid 
substitutions and changes that are unique to insulin glargine. 
As opposed to intermediate-acting insulin formulations, such as NPH insulin, 
the pharmacokinetic profi le of insulin glargine has a more peak-less action profi le, 
thus mimicking basal insulin secretion more closely. In type 1 diabetic patients under 
isoglycemic clamps for 24-h, Lepore et al. (2000) observed an earlier onset of action 
for NPH insulin compared to insulin glargine, while the effect of insulin glargine lasted 
8 h more than NPH insulin. Addtionally, in the study by Lepore and coworkers, insulin 
glargine had lower inter-subject variability than NPH insulin. Other forms of long-acting 
insulin such as insulin detemir are commercially-available for use in human medicine. 
However other specifi c analogues and their activities will not be discussed here as NPH 
insulin and insulin glargine are the main focus of interest in the present research.
Altering the structure of insulin impacts its affi nity for insulin receptors, 
residence time on receptors, and affi nity for other receptors such as IGF-I receptors. In 
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vitro studies using a variety of cell types have shown some interesting characteristics 
about insulin glargine activity. As NPH insulin is simply a protaminated form of 
regular insulin, the receptor affi nity and pharmacodynamic characteristics of NPH 
insulin are not different from unaltered human insulin. Therefore, the following 
discussion will focus on these characteristics for insulin glargine only.
A study by Kurtzhals et al. (2000), examined the binding, metabolic, and 
mitogenic activities of 8 insulin formulations, including native human insulin and 
insulin glargine. In the human osteosarcoma cell line Saos/B10, insulin glargine 
exhibited nearly 8-times the mitogenic potency of normal human insulin. As was noted 
in that paper, the Saos/B10 cells express approximately 30,000 IGF-I receptors and 
less than 1,000 insulin receptors per cell. The abnormal ratio of IGF-I:insulin receptors 
may be very infl uential in the mitogenic responses observed in that particular study.
Other similar studies found that insulin glargine was only slightly more 
mitogenic than normal insulin. In using cardiac myoblasts and cardiomyocytes, Bahr 
et al., (1997) showed that insulin glargine had only slightly greater affi nity for IGF-I 
receptors when compared to human insulin. In normal and transformed human breast 
epithelial cells, Staiger et al. (2007), measured DNA synthesis by 3[H]thymidine 
incorporation in the presence of varying concentrations on insulin and insulin glargine. 
In the MCF-10 cells or normal breast epithelial cells, there were no statistically 
signifi cant differences between insulin and insulin glargine at any concentrations 
tested for DNA synthesis. Similarly, in the transformed MCF-7 human breast 
carcinoma cells, there were no differences between insulin and insulin glargine at any 
of the concentrations tested. 
Use of insulin and insulin analogues in lactating dairy cattle
The importance of insulin in metabolism and homeorhesis in lactating dairy 
cattle has been a focal point in numerous research groups over the years. Some dairy 
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cattle research has incorporated the use of altered insulin products to study the effects 
of insulin in cows. For example, Hayirli et al., (2002) used Humulin (Ultralente 
human insulin rDNA origin in extended zinc suspension) to evaluate effects of 
insulin on cow health and metabolism immediately postpartum. The insulin used in 
that study is no longer commercially available. However, the action profi le of the 
Ultralente insulin would be somewhat similar to NPH insulin described earlier in 
this review, though the onset of action may be slightly later for Ultralente insulin 
and it may have higher insulin activity (Lepore et al., 2000). In the study by Hayirli 
and coworkers, cows receiving the lowest dose of slow-release insulin (0.14 IU/kg 
BW) by intramuscular injection appeared to have the most positive responses to 
treatment as evidenced by increased dry matter intake and milk yield, and reduced 
liver triglyceride. Milk composition was not reported for this experiment. In a brief 
review of the literature, it appears that protamine zinc insulins have been used less 
than a handful of times in dairy cattle, and most often this research has focused on the 
reduction of hepatic lipidosis and ketosis (e.g. Sakai et al., 1993; Hayirli et al., 2002). 
Additionally, the introduction of true long-acting insulins for use in humans has been 
a recent occurrence. Insulin glargine was approved for use in humans by the FDA 
in 2000 while insulin detemir received FDA approval in 2005. The pharmacokinetic 
and pharmacodynamic profi les of these analogues are substantially different than 
protamine insulins and could be used in dairy cattle research to elevate insulin activity.
RESEARCH OBJECTIVES
Continuing to fi ne tune dairy cow nutrition management to improve protein 
effi ciency within the cow has large implications for both the environment and the 
bottom-line of dairy farms. As we continue to improve conversion effi ciencies of 
feed nutrients and N into milk protein, less N will be wasted and excreted into the 
environment. Based on work with hyperinsulinemic-euglycemic clamps in lactating 
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dairy cows, it appears that milk protein synthesis under current management 
conditions is not maximized. While insulin is given the credit for boosting milk 
protein production in hyperinsulinemic-euglycemic clamp studies, the confounding 
effect of exogenous glucose, and thus energy, cannot be ignored. Ideally, the effects 
of insulin could be studied without large decreases in glycemia and the associated 
confounding effects of hypoglycemia. 
In human medicine, insulin products and analogues exist that have extended 
duration of action, such as insulin glargine. The main hypothesis of the research 
presented within this dissertation is that slow-release insulins could be used in 
lactating dairy cows to study the effects of elevated insulin activity on milk protein 
synthesis, without the need to provide exogenous glucose to maintain relatively 
normal glycemia. As insulin affects and interacts with the mTOR signaling pathway, 
it is proposed that increased protein production will occur in cows treated with NPH 
insulin and insulin glargine, and that this will occur through stimulation of the insulin 
signaling pathway in the mammary gland, including phosphorylation and activation of 
Akt and mTOR, as evidenced by downstream phosphorylation changes in rpS6.
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CHAPTER THREE: RESPONSES OF LACTATING DAIRY COWS TO 
INCREASING DOSES OF TWO FORMS OF SLOW-RELEASE INSULIN
ABSTRACT
This study investigated the effect of increasing doses of two different types of 
slow-release insulin on the 24-h profi les of plasma glucose and insulin concentrations 
in lactating dairy cows. The study was carried out in two separately analyzed 
experiments investigating the effects of Humulin-N (H), a neutral protamine hagedorn 
insulin, and insulin glargine (L), an insulin analogue, at doses of 0 (control), 0.1, 0.2, 
and 0.4 IU/kg BW in a randomized complete block design. Sixteen cows were used 
for each insulin type, resulting in n = 4 for each dose within insulin type. Cows were 
fi tted with a single jugular catheter on the day before the study. On the day of the 
study, cows were given treatments by subcutaneous injection of either sterile water 
or the designated insulin type and dose. Blood samples were taken hourly from the 
jugular catheter. Subcutaneous injection of both H and L resulted in linear decreases 
in plasma glucose concentrations (P < 0.001). Plasma insulin concentration linearly 
increased with increasing dose of H (P < 0.001). Though we were able to measure 
insulin in samples from cows treated with H, we were unable to obtain accurate insulin 
concentrations for samples from cows treated with L. We attempted to measure overall 
insulin concentrations and metabolites of L by a commercially-available ELISA 
and a commercially-available RIA kit, but did not retrieve values that we felt truly 
represent the amount of insulin activity being exhibited during this treatment. Though 
we were unable to measure actual insulin concentrations in cows treated with L, the 
observation of reduced plasma glucose in cows treated with L serves as a proxy for 
overall insulin activity. Both slow-release insulin products elicited insulin-like activity 
in lactating dairy cows, as evidenced by reduced plasma glucose concentrations. Given 
these results, the potential exists to use both H and L to study the effects of insulin 
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in lactating dairy cows without the confounding effect of severe hypoglycemia or 
concurrent provision of glucose during treatment.
INTRODUCTION
The use of hyperinsulinemic-euglycemic clamps in experimental contexts has 
been useful over the last 30 years as an in vivo model to examine whole-body insulin 
sensitivity. First described in human subjects (DeFronzo et al., 1979), the concept of 
increasing circulating insulin concentrations by a constant insulin infusion rate with 
concurrent glucose infusion at a varied rate to maintain euglycemia has become the 
gold standard method for examining whole-body insulin responsiveness. 
In lactating dairy cows, one of the fi rst experiments using the 
hyperinsulinemic-euglycemic clamp technique was carried out to evaluate the effect of 
insulin on milk synthesis (McGuire et al., 1995b) and components of the insulin-like 
growth factor system (McGuire et al., 1995a). During the 4-d clamp period in which 
circulating insulin concentrations were elevated more than fi ve-fold above baseline 
concentrations, McGuire and coworkers observed a 0.07 kg/d increase in milk protein 
yield, representing a 7% increase in milk protein output during the clamp period. In 
a subsequent experiment from the same group at Cornell University, Griinari et al., 
(1997a; 1997b) used the clamp technique in mid-lactation cows to elevate circulating 
insulin concentrations four-fold above baseline in conjunction with abomasal infusion 
of casein. During the clamp and abomasal infusion, milk protein yield increased 
0.23 kg/d or 28% above baseline production. With provision of additional protein 
substrate in the abomasum in the form of casein and amino acids, Mackle et al. (1999) 
observed a 25% increase in milk protein output under hyperinsulinemic-euglycemic 
clamp conditions accompanied by a decrease in circulating essential amino acid 
concentrations, increased mammary blood fl ow, increased extraction effi ciency of 
amino acids, and increased glucose uptake (Mackle et al., 2000). These results suggest 
40
that maximal milk protein production by the mammary gland has not been fully 
reached with common lactating rations in well-fed cows. Additionally, it appears that 
the hyperinsulinemic-euglycemic clamp alters mammary gland uptake and metabolism 
of protein substrates.
All of the studies referenced above indicate that insulin infl uences mammary 
gland protein synthesis. However, interpretation of results from hyperinsulinemic-
euglycemic clamps is not that simple. The confounding effect of co-infusion of both 
insulin and exogenous glucose make it impossible to determine if the results are 
due to the effects of insulin, glucose, or both. During hyperinsulinemic-euglycemic 
clamps, signifi cant amounts of glucose, and thus energy, are being infused into 
the cow. In the study by Mackle (1999), the amount of glucose infused per day 
(3.336 kg) was the equivalent of 12.2 Mcal NEL/d (the NEL value used for glucose 
calculation was described by Leonard and Block (1997) as 3.66 Mcal NEL/kg), which 
is a considerable amount of energy. Additionally, infusion of glucose intravenously 
(Amaral et al., 1990) and into the duodenum (Rulquin et al., 2004) can also increase 
milk protein yield.
When administered by itself, insulin is commonly associated with reduced 
milk production and lowered blood glucose. Schmidt (1966) administered short-
acting insulin subcutaneously in primiparous cows and observed an increase in 
milk protein percentage during insulin treatment, but no change in protein yield. 
Twice-daily injections of protamine zinc insulin in lactating dairy cows reduced total 
milk yield and blood glucose (Kronfeld et al., 1963). When given alone, the effect 
of insulin is also confounded by the effect of reduced glycemia. So, regardless of 
how the effects of insulin are investigated, either infused glucose or hypoglycemia 
may confound the results and interpretation. Ideally, the effects of insulin should 
be evaluated in situations without signifi cant changes in glycemia or provision of 
additional glucose.
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Numerous types of insulin and insulin analogues are used in human medicine 
to treat diabetes and their uses vary depending type and severity of diabetes, time 
of day or timing of last meal, and other varying factors (Sheldon et al., 2009). 
Commercially-available insulins and insulin analogues come in rapid-acting, 
intermediate-acting, and long-acting formulations. Insulin glargine is a recombinant, 
human insulin analogue and is classifi ed as a long-acting insulin, lasting up to 24 h in 
duration (Goykhman et al., 2009). Insulin glargine differs from native human insulin 
with a glycine substitution for an asparagine residue at position A21 and addition of 
two arginine residues on the carboxy-end of the B-chain at positions B31 and B32 
(Bolli and Owens, 2000). These amino acid substitutions to this analogue shift the 
isoelectric point of the molecule from pH 5.4 to 6.8 and make it more soluble in a 
more acidic solution. When insulin glargine is given subcutaneously, it precipitates 
at the more neutral pH of the injection site, slowly dissipating and being absorbed 
over a prolonged period of time. As opposed to other slow-release or intermediate-
acting insulin formulations, such as neutral protamine hagedorn (NPH) insulins, the 
pharmacokinetic profi le of insulin glargine has a more peak-less action profi le, thus 
mimicking basal insulin secretion more closely. These characteristics make insulin 
glargine an option to explore the effects of elevated insulin activity in dairy cows 
without the need to infuse glucose to maintain euglycemia.
The use of long-acting or slow-release insulin in lactating dairy cattle has been 
limited. Hayirli et al. (2002) administered increasing doses of protamine zinc insulin 
(Humulin, Ultralente human insulin rDNA origin in extended zinc suspension) via 
intramuscular injection to early lactation cows on d 3 postpartum. Increasing dose of 
slow-release insulin in that study tended to increase milk yield in the early lactation 
cows, with cows receiving a dose of 0.14 IU/kg BW yielding 4 kg/d more from d 3 
to 5 postpartum than controls. The quadratic effect of increased milk yield may have 
been due to a quadratic increase in dry matter intake (DMI). A once-daily injection 
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of 0.14 IU/kg BW resulted in serum insulin concentrations that were 1.75 times 
higher than the control in the fi rst 24 h after injection. Meanwhile, circulating glucose 
concentrations were 5.2 mg/dl lower for the 0.14 IU dose. Effects of slow-release 
insulin on plasma glucose and insulin were diminished by 24 h after the fi rst injection.
The objective of the present study was to evaluate the plasma profi les of 
glucose and insulin for 24 h following injection of increasing doses of two different 
forms of slow-release insulin. A NPH insulin (Humulin-N, 100 IU/ml human insulin, 
rDNA origin, Eli Lilly, Indianapolis, IN) was selected as one form of insulin in 
this experiment because of previous use of a similar type in dairy cows (Hayirli 
et al., 2002). Insulin glargine (Lantus, 100 IU/ml insulin glargine [rDNA origin], 
Sanofi -Aventis, Bridgewater, NJ) was selected based on its pharmacokinetic and 
pharmacodynamic characteristics.
MATERIALS AND METHODS
Animals, Experimental Design, and Treatments
The Cornell University Institutional Animal Care and Use Committee 
approved all procedures involving cows prior to the onset of the experiment. Thirty-
two multiparous Holstein cows were adapted to a common TMR for 7 d before the day 
of treatment. Cows were divided into four groups containing eight cows each, based 
on DIM. Within each group, cows were randomly assigned to one of four treatments. 
Treatments included control (sterile water), low (0.1 IU/kg BW), medium (0.2 IU/kg 
BW), and high (0.4 IU/kg BW) doses of slow-release insulin. Cows were weighed 
once on the day before treatment commenced, after the morning milking and before 
daily feed delivery, to determine the total dose of slow-release insulin. For the fi rst two 
groups of cows (237 ± 11 DIM, X ± SD), Humulin-N, (H; 100 IU/ml human insulin 
[rDNA origin] isophane suspension, Eli Lilly, Indianapolis, IN) was the form of slow-
release insulin. For the second part of the experiment, insulin glargine, also known as 
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Lantus (L; 100 IU/ml insulin glargine [rDNA origin], Sanofi -Aventis, Bridgewater, 
NJ) was administered as the form of slow-release insulin to two groups of cows (213 ± 
10 DIM, X ± SD). 
On the day before treatment commenced in all groups, cows were fi tted with 
an indwelling jugular catheter (Tygon Microbore Tubing, 1.778 mm o.d. x 1.016 
mm i.d., Norton Performance Plastics, Akron, OH). On the day of treatment, two 
blood samples were collected prior to administration of either sterile water or slow-
release insulin doses, and were used for covariate data in the statistical analysis. At 
0900 h, cows were given treatments via subcutaneous injection in the neck. Blood 
samples were collected hourly for 24 h via jugular catheter and blood was transferred 
to tubes containing sodium heparin (30 U heparin/ml of blood). Blood samples 
were centrifuged (3,000 x g for 20 min at 4º C) and plasma was harvested into three 
aliquots, quickly frozen with liquid N, and then stored at -20º C until analysis for 
glucose and insulin. 
A common TMR was fed to all cows ad libitum and was formulated to 
meet NRC nutrient recommendations (National Research Council, 2001). During 
the diet adaptation period, fresh feed was provided each morning at 0900 h, orts 
were weighed and recorded daily, and water was made available at all times. On the 
day of sampling, feed was delivered hourly to minimize fl uctuations in circulating 
metabolites and hormones infl uenced by feed intake. Samples of the TMR were 
taken on the day of treatment and sent to Cumberland Valley Analytical Services 
(Hagerstown, MD) for analysis using wet chemistry techniques for CP (AOAC, 
2000), acid detergent insoluble CP [CP determined using AOAC (2000) after 
acid detergent extraction (AOAC, 2000)], neutral detergent insoluble CP [AOAC 
(2000) method for CP after neutral detergent extraction (Van Soest et al., 1991)], 
soluble CP, (Krishnamoorthy et al., 1982), ADF (AOAC, 2000), NDF (AOAC, 2000), 
and ash (AOAC, 2000). Dietary ingredients and chemical composition of the basal 
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TMR is reported in Table 3-1. Cows were milked three times daily at 0700, 1500, and 
2300 h during the adaptation period and on the day of treatment and sample collection. 
Plasma Hormone and Metabolite Analysis
Plasma concentrations of glucose were determined by enzymatic analysis 
(glucose oxidase) using commercially-available reagents (#P7119 PGO Enzyme 
Preparation, #F5803 3,3’Dimethoxy benzidine dihydrochloride; Sigma Aldrich, St. 
Louis, MO). Intra-assay and interassay coeffi cients of variation (CV) for glucose 
Table 3-1. Dietary ingredients and nutrient composition 
of the basal diet (DM basis)
Ingredient, % Content
Corn silage 40.5
Alfalfa silage 16.1
Concentrate mix1 21.9
Corn meal 16.0
Corn distillers grain 5.5
Energy and nutrients2
  NEL, Mcal/kg 1.68
  CP 16.1
  Soluble Protein, % CP 35.1
  RDP, % CP 72.6
  ADF 19.3
  NDF 33.6
  NFC 41.8
  Ash 6.3
  Calcium 0.70
  Phosphorus 0.42
  Magnesium 0.31
  Potassium 1.27
  Sodium 0.4
  Iron, ppm 185.0
  Manganese, ppm 62.7
  Zinc, ppm 83.3
  Copper, ppm 16.0
1 The concentrate mix was comprised of (DM basis): 35.5% corn germ meal; 29.0% 
wheat midds, 12.6% canola meal, 5.6% calcium carbonate, 4.7% whey permeate, 
3.9% blood meal, 2.5% sodium bicarbonate, 2.2% salt, 2.0% urea, 0.8% Optigen 
II (Alltech, Lexington, KY), 0.6% magnesium oxide, 0.2% calcium sulfate, 0.2% 
selenium 0.06%, 0.1% trace minerals, 0.1% Agrado (Novus International, Inc., St. 
Louis, MO), 0.1% vitamin A/D/E, and 0.1% Rumensin (Elanco, Indianapolis, IN).
2 Values represent average values of TMR samples taken on each day of treatment.
45
analysis were 2.6 and 3.3%, respectively. Spectrophotometric readings were 
made using a Versamax tunable microplate reader (Molecular Devices, Sunnyvale, CA). 
Plasma insulin concentrations were measured using two commercially-
available kits. First, a bovine insulin ELISA kit reported to exhibit 28% cross-reactivity 
with insulin glargine (Mercodia Bovine Insulin ELISA #10-1201-01, Uppsala, 
Sweden) was used to measure the insulin values in the hourly plasma samples. Intra-
assay and interassay CV for the ELISA were 4.3 and 6.4%, respectively. Plasma 
insulin concentrations were also determined by a commercially-available RIA kit 
which has 90% cross-reactivity with native bovine insulin (#PI-12K Porcine Insulin 
Radioimmunoassay, LINCO Research, St. Charles, MO). Intra-assay and interassay 
CV for the RIA insulin analysis were both 10%. 
Statistical Analysis
Data from the H and L treatments were analyzed separately, as both treatments 
were not represented in all groups. With each type of slow-release insulin, data 
were analyzed using the MIXED procedure of SAS (2001). Fixed effects in the 
model included treatment dose, hour, and the interaction of dose and hour. Repeated 
measures for hour were included in the REPEATED statement. Group was included 
as a random effect in the model. Covariate data points collected before treatments 
commenced were used for covariate adjustment in the model.
RESULTS AND DISCUSSION
Sixteen cows completed the fi rst part of the experiment utilizing H as the form 
of slow-release insulin. For the L portion of the experiment, one control cow was 
dropped from the experiment before treatment commenced due to a mobility issue 
unrelated to the experiment, resulting in 15 cows being used in the data analysis. On 
the day of treatment, DMI was not different between doses for cows given either type 
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of slow-release insulin. Dry matter intakes for cows treated with H were as follows: 
27.9, 27.5, 29.4, and 29.0 ± 1.61 kg for the 0, 0.1, 0.2, and 0.4 doses, respectively (P 
= 0.83). For cows treated with L, DMI on the day of treatment were as follows: 29.1, 
29.5, 28.3, and 25.7 ± 2.5 kg for the 0, 0.1, 0.2, and 0.4 doses respectively (P = 0.62). 
Though there was not an overall effect of treatment dose on DMI for the cows treated 
with L, the cows treated with the highest dose of L had numerically lower DMI, 
but there was no linear effect of L dose on DMI (Linear: P = 0.28). In ruminants, 
the effects of insulin on intake are variable. In a study designed to test the effect 
of insulin on long- and short-term feeding behavior, Baile and Mayer (1968) did 
not observe any changes in intake with insulin treatment and severe hypoglycemia. 
Insulin effects on DMI were more variable in sheep (Deetz et al., 1980), sometimes 
causing a decrease in intake while at other times having no effect on intake depending 
on dose or route of administration. Hayirli et al., (2002) observed a tendency for 
a quadratic effect of slow-release insulin on intake, with early lactation cows 
receiving a dose of 0.14 IU/kg having higher intakes than cows on other treatments. 
In the experiments by Kronfeld et al. (1963), numerous cows became recumbent 
and depressed during treatment with successive doses of insulin, and during these 
severe hypoglycemic episodes, the authors report that the cows did not eat. Thus it 
appears that insulin can have varied effects on ruminants, depending on the dosage 
rate and type of insulin administered. The overall goal of the present experiment is 
to determine if slow-release insulins can be used to elevate insulin activity without 
the need to infuse glucose to maintain glycemia within normal ranges. With the 
observation of a numerical decrease in intake at the highest dose of L, we are hesitant 
to use that dose in studies of longer duration as effects of severe hypoglycemia 
include anorexia.
Plasma glucose concentrations decreased linearly with increasing dose of 
slow-release insulin for cows administered both the H and L treatments. Plasma 
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Figure 3-1. Plasma glucose concentrations for cows injected subcutaneously with 
sterile water (–●–) or 0.1 (–□–), 0.2 (–■–), or 0.4 (–■–) IU of Humulin-N per kg of 
BW. Probabilities of significance for effects of dose, hour, and dose x hour interaction 
were P < 0.001, P < 0.001, and P < 0.001, respectively. A linear decrease (P < 0.001) 
in plasma glucose was observed with increasing dose of Humulin-N treatment.
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Figure 3-2. Plasma glucose concentrations for cows injected subcutaneously with 
sterile water (–●–) or 0.1 (–▲–), 0.2 (–▲–), or 0.4 (–▲–) IU of insulin glargine 
per kg of BW. Probabilities of significance for effects of dose, hour, and dose x hour 
interaction were P = 0.002, P = 0.002, and P = 0.32, respectively. A linear decrease 
(P < 0.001) in plasma glucose was observed with increasing dose of insulin glargine 
treatment.
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glucose responses to subcutaneous H and L injections are shown in Figures 3-1 and 
3-2, respectively. Based on work with a similar slow-release insulin by Hayirli et al. 
(2002), it was expected that H would decrease plasma glucose concentrations in this 
experiment. Over the 24-h sampling period, plasma glucose concentrations were 3.1, 
5.6, and 9.4% lower for the 0.1, 0.2, and 0.4 IU/kg BW treatments of H, respectively. 
Glucose concentrations were 62.1, 60.2, 58.7, and 56.3 ± 0.74 mg/dl for the control, 
0.1, 0.2, and 0.4 IU/kg BW treatments of H, respectively (effect of dose: P < 0.001; 
linear: P < 0.001). Though the reductions in plasma glucose observed in this study 
were not as large as the decreases observed by Hayirli et al. (2002), it should be noted 
that the type of slow-release insulin used in that study was not exactly the same as the 
type used in this study. Additionally, the cows used in the present study were in late 
lactation, as opposed to the early postpartum cows used in the experiment by Hayirli 
and coworkers. Over the course of the 24-h sampling period, the 95% confi dence 
intervals for the mean plasma glucose concentrations were 60.7 – 63.6, 58.7 – 61.7, 
57.2 – 60.2, and 54.9 – 57.8 mg/dl for the control, 0.1, 0.2, and 0.4 IU/kg BW 
treatments respectively. Plasma glucose reached the lowest concentrations near the 6 
and 7 h timepoints following injection.
For the cows treated with subcutaneous injections of L, plasma glucose 
concentrations were 5.6, 7.5, and 17.9% lower than the controls for the 0.1, 0.2, and 
0.4 IU/kg BW doses, respectively (effect of dose: P < 0.001; linear: P < 0.001). Over 
the 24-h sampling period, glucose concentrations were 66.0, 62.3, 61.0, and 54.1 ± 
1.94 mg/dl for the control, 0.1, 0.2, and 0.4 IU/kg BW treatments of L, respectively. 
Over the course of the 24-h sampling period, the 95% confi dence intervals for the 
mean plasma glucose concentrations were 62.0 – 70.0, 59.3 – 65.2, 57.6 – 64.4, and 
50.2 – 58.0 mg/dl for the control, 0.1, 0.2, and 0.4 IU/kg BW treatments respectively. 
Plasma glucose reached the lowest concentrations near the 12 h timepoint following 
injection. To our knowledge, L has never been administered to lactating dairy cows 
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or any ruminants. Though it was expected that L would exhibit insulin-like activity 
in dairy cows, we were unsure to what extent plasma glucose would be decreased 
following L injection. 
As our goal of these experiments was to elevate insulin activity without 
the negative consequences resulting from severe hypoglycemia (e.g. anorexia, 
unconsciousness, disturbed behavior), we are hesitant to proceed the largest doses 
of either form of slow-release insulin with once-daily dose for longer term studies. 
During the 24-h sampling period, on the highest doses of both H and L, individual 
cows had plasma glucose concentrations near 20 mg/dl, which is not within normal 
ranges for lactating dairy cows under normal management conditions. The 95% 
confi dence intervals of the mean plasma glucose concentrations for cows treated 
with the highest doses of both H and L suggest that cows treated with these doses 
did indeed enter a hypoglycemic state at times, though no visual signs of severe 
hypoglycemia were observed.
The fi rst insulin assay used to attempt to measure plasma insulin was the 
Mercodia Bovine Insulin ELISA (Mercodia, Uppsala, Sweden). The cross-reactivity 
data from Mercodia stated the ELISA exhibited 28% cross-reactivity with L. Many 
other insulin assays do not state cross-reactivity with L, so this ELISA seemed like a 
logical starting point for insulin analyses. 
When plasma insulin was measured by the Mercodia Bovine Insulin ELISA, a 
linear increase in plasma insulin was observed with increasing dose of H (Figure 3-3). 
For cows treated with H, plasma insulin was increased by 12.1, 25.6, and 67.9% for 
the 0.1, 0.2, and 0.4 IU/kg BW doses, respectively (effect of dose: P < 0.001; linear: 
P < 0.001). Insulin concentrations were 1.30, 1.46, 1.64, and 2.19 ± 0.143 ng/ml 
for the control, 0.1, 0.2, and 0.4 IU/kg BW doses of H, respectively. On the other 
hand, when looking at the cows treated with L, the results from the ELISA suggest 
that the assay does not exhibit cross-reactivity with the insulin glargine metabolites. 
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Figure 3-4. Plasma insulin values, as measured by the Mercodia Bovine Insulin 
ELISA, for cows injected subcutaneously with sterile water (–●–) or 0.1 (–▲–), 0.2 
(–▲–), or 0.4 (–▲–) IU of insulin glargine per kg of BW. Probabilities of significance 
for effects of dose, hour, and dose x hour interaction were P < 0.001, P = 0.002, and 
P = 0.012, respectively. A linear increase (P < 0.001) in ELISA insulin values was 
observed with increasing dose of insulin glargine treatment.
Figure 3-3. Plasma insulin values, as measured by the Mercodia Bovine Insulin 
ELISA, for cows injected subcutaneously with sterile water (–●–) or 0.1 (–□–), 0.2 
(–■–), or 0.4 (–■–) IU of Humulin-N per kg of BW. Probabilities of significance for 
effects of dose, hour, and dose x hour interaction were P < 0.001, P < 0.001, and P = 
0.29, respectively. A linear increase (P < 0.001) in plasma insulin was observed with 
increasing dose of Humulin-N treatment.
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Using unadjusted data from the ELISA, cows treated with increasing dose of L had 
linearly lower values in the ELISA (Figure 3-4) and the least square means for the 
24-h sampling period were 1.21, 0.89, 0.79, and 0.58 ± 0.092 ng/ml for control, 0.1, 
0.2, and 0.4 IU/kg BW doses of L, respectively (effect of dose: P < 0.001; linear: P < 
0.001). Intuitively, if the ELISA did in fact cross-react with L then, even with reduced 
overall cross-reactivity, greater values from the ELISA would be expected with 
increasing doses of insulin glargine. This was not the case, suggesting a few plausible 
explanations. First, the ELISA may be detecting endogenous concentrations of native 
bovine insulin. With extra insulin-activity in the system, it would seem plausible 
that the pancreas would secrete less insulin. Exogenous insulin supplied to an in situ 
perfused pancreas suppressed endogenous insulin secretion (Stagner et al., 1986).  The 
work by Stagner et al. (1986) supports the concept that endogenous insulin production 
would be down-regulated in the present study for cows treated with L. Alternatively, 
the insulin glargine metabolites in the plasma samples may interfere with the ELISA 
antibody’s ability to bind with insulin. That is, as more insulin glargine metabolites 
are in circulation with increasing dose of L, there may be increasing interference 
in the assay leading to reduced values in the ELISA. Finally, in detailed work with 
human insulin assays and detection of insulin glargine, Agin et al., (2007) forced 
solubilization of the insulin glargine molecule into its metabolites before submitting it 
to the assays, thus mimicking the natural precipitation of insulin glargine that occurs 
as it adjusts to physiological pH. If the cross-reactivity of insulin glargine with the 
ELISA was tested on the insulin glargine molecule, as opposed to breaking it down 
into its metabolites and then testing the cross-reactivity, the results reported in the kit 
information may be inaccurate. 
To try to obtain a better idea of how much insulin-like activity was present 
in the cows treated with L, another insulin assay was used. The results reported here 
represent unadjusted values from the porcine insulin RIA, and as previously noted 
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Figure 3-6. Plasma insulin values, as measured by RIA, for cows injected 
subcutaneously with sterile water (–●–) or 0.1 (–▲–), 0.2 (–▲–), or 0.4 (–▲–) IU of 
insulin glargine per kg of BW. Probabilities of significance for effects of dose, hour, 
and dose x hour interaction were P = 0.14, P < 0.001, and P = 0.23, respectively. A 
linear effect of dose (P = 0.07) on RIA insulin values was observed.
Figure 3-5. Plasma insulin values, as measured by RIA, for cows injected 
subcutaneously with sterile water (–●–) or 0.1 (–□–), 0.2 (–■–), or 0.4 (–■–) IU of 
Humulin-N per kg of BW. Probabilities of significance for effects of dose, hour, and 
dose x hour interaction were P < 0.001, P < 0.001, and P = 0.28, respectively. A 
linear increase (P < 0.001) in RIA insulin values was observed with increasing dose of 
Humulin-N treatment.
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this assay exhibits 90% cross-reactivity with bovine insulin. For cows treated with 
H, a linear increase (P < 0.001) in plasma insulin concentrations was observed with 
increasing dose of H (1.02, 1.15, 1.08, and 1.57 ± 0.097 ng/ml for control, 0.1, 0.2, 
and 0.4 IU/kg BW doses, respectively). The 24-h profi le of insulin values for cows 
treated with H is shown in Figure 3-5. When results from the RIA were compared 
with those from the ELISA, the insulin values obtained with the RIA were between 
21 and 34% lower than those obtained from the ELISA, keeping in mind that the RIA 
results were not corrected for the 90% cross-reactivity. Thus, with correction for cross-
reactivity, the difference would become smaller.
For the cows treated with L, there was no overall effect of treatment for the 
values obtained from the RIA (P = 0.14; 1.22, 1.02, 0.99, and 1.02 ± 0.089 ng/ml for 
control, 0.1, 0.2, and 0.4 IU/kg BW treatments of L, respectively, with no adjustment 
for assay 90% cross-reactivity of the RIA). The 24-h profi les of insulin values 
Figure 3-7. Human insulin (A), bovine insulin (B), and insulin glargine (C) amino 
acid homology. Bovine insulin differs from human insulin by three amino acids, 
including an Ala substitution for Thr at amino acid 8 on the A chain and amino acid 
30 on the B chain, and a Val substitution for Ile at amino acid 10 on the A chain. For 
insulin glargine, the base amino acid structure is similar to human insulin except for a 
Gly substitution for Asn on the carboxyl end of the A chain and the addition of two Arg 
residues on the carboxyl end of the B chain.
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obtained by RIA are shown in Figure 3-6 and there was a linear effect of L on insulin 
values for this assay (P = 0.07). Taken collectively with the results from the ELISA, it 
would seem plausible that the insulin glargine metabolites interfere with the antibody 
binding in the ELISA, thus showing reduced values in the assay for cows treated with 
increasing doses of L. 
In selection of the assays used to measure insulin-activity following injection 
with slow-release insulins, the cross-reactivity of the two slow-release insulins to the 
antibodies in the assays was considered. Humulin-N is produced by a laboratory strain of 
Escherichia coli that has been genetically altered to produce human insulin, making the 
structure of H homologous to human insulin. As human insulin and bovine insulin are 
different by only three amino acids (Figure 3-7), depending on epitope location on the 
antibody, commercially-available insulin assays should be able measure H in plasma.
On the other hand, L has important structural modifi cations (Figure 3-7) that 
alter its ability to be detected by commercially-available insulin assays. When given 
subcutaneously, the insulin glargine molecule is solubilized into two metabolites, M1 
and M2 (Kuerzel et al., 2003; Agin et al., 2007). These metabolites retain some of 
the same amino acid changes as the native glargine molecule. The cross-reactivity of 
L and its metabolites with antibodies to human insulin is lower than reactivity with 
native insulin. Immunoaffi nity chromatography followed by liquid chromatography 
mass spectrometry can detect insulin glargine metabolites in urine (Thomas et al., 
2007), however, no urine samples were taken during this set of experiments for that 
type of analysis. In later experiments, this method could be explored as a potential 
way to measure glargine metabolites in bovine urine.
Though we were unable to precisely measure insulin in the plasma samples 
taken from cows treated with L, our overall goal was to fi nd a research model that 
could be used to extend the information learned from hyperinsulinemic-euglycemic 
clamps. Both slow-release insulin types reported here exhibited insulin activity in 
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lactating dairy cows, as evidenced by reduced plasma glucose concentrations during 
the 24-h period following injection. 
During hyperinsulinemic-euglycemic clamps, oftentimes the goal is to 
maintain glycemia within 10% of baseline glucose concentrations (Mackle et al., 
1999). In consideration of the data reported here, for all treatment doses and insulin 
types except the 0.4 IU/kg BW dose of insulin glargine, all mean plasma glucose 
concentrations were within 10 percent of the mean plasma glucose concentrations for 
the control treatment.
CONCLUSIONS
Both forms of slow-release insulin were effectively able to reduce circulating 
plasma glucose concentrations in lactating cows without severe hypoglycemia. By 
using slow-release insulins and eliminating the need for provision of additional 
glucose, there is potential to use these forms of insulin as an alternative to 
hyperinsulinemic-euglycemic clamps to investigate the effects of elevated insulin 
activity in lactating dairy cows. Though we were not able to exactly measure overall 
insulin concentrations in cows treated with insulin glargine, the response of reduced 
plasma glucose concentrations during treatment serves as a proxy for insulin activity 
within these cows.
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CHAPTER FOUR: EFFECTS OF SLOW-RELEASE INSULIN ON MILK AND 
COMPONENT PRODUCTION BY LACTATING DAIRY COWS
ABSTRACT
This study investigated the effect of two different types of slow-release insulin 
on milk production and composition in lactating dairy cows. Thirty multiparous cows 
averaging 88 days in milk were assigned to one of three treatments in a randomized 
complete block design. Treatments consisted of control (C), Humulin-N (H), and 
insulin glargine (L). The H and L treatments were administered twice daily at 12-h 
intervals via subcutaneous injection for 10 d. Cows were milked twice daily and milk 
composition was determined every other day. Mammary biopsies were performed on d 
11 and mammary proteins extracted from the biopsies were analyzed by Western blot 
for components of insulin and mammalian target of rapamycin signaling pathways. 
There were no effects of treatment on DMI or milk yield (P > 0.10). Treatment with 
both forms of slow-release insulin increased milk protein content and milk protein 
yield was higher for cows treated with L. Milk fat content and yield were higher for 
cows treated with L compared with controls, but treatment with H did not affect milk 
fat content or yield. Lactose content was reduced by treatment with both slow-release 
insulins. Yields of milk casein were higher for cows treated with both forms of slow-
release insulin, but the overall casein content as a percentage of true protein did not 
differ between treatment groups. Plasma glucose concentrations were lower for cows 
treated with both L and H compared to controls. Coinciding with the observation 
of higher protein yield, plasma urea nitrogen concentrations were lower for cows 
treated with L. Plasma NEFA concentrations were higher for cows treated with H 
as compared to control cows. Western blot analysis of mammary tissue collected by 
biopsy indicated that the ratio of phosphorylated Akt to total Akt differed by treatment 
(P = 0.05) and was greatest for cows treated with H. The ratio of phosphorylated 
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rpS6 to total rpS6 did not differ by treatment (P = 0.60). Modestly elevating insulin 
activity in lactating dairy cows by twice-daily subcutaneous injections of both H and 
L altered mammary metabolism and production of milk protein and fat. These forms 
of insulin may provide a model to study the effects of insulin without provision of 
exogenous glucose or severe hypoglycemia, but their effects on cell signaling within 
the mammary gland need further investigation.
INTRODUCTION
Insulin, a polypeptide hormone secreted by the β-cells of the islets of 
Langerhans in the pancreas, is a potent regulator of energetic metabolism and nutrient 
partitioning. Insulin exerts anabolic effects on tissues in both nonruminants and 
ruminants and acts to stimulate glucose uptake by muscle and adipose, stimulate 
glycogen synthesis, and also inhibit lipolysis, gluconeogenesis, and glycogenolysis. 
Although mammary uptake of glucose is insulin-independent (Laarveld et al., 
1981; Zhao and Keating, 2007), insulin is still an important hormone in milk and 
milk component synthesis because of its roles in nutrient partitioning and energy 
metabolism (Brockman and Laarveld, 1986). Studying the effects of insulin in 
ruminants and dairy cows is a challenge because hypoglycemia can result when 
substantial doses are administered, resulting in decreased milk yield and dry matter 
intake (e.g. Kronfeld et al., 1963; Schmidt, 1966).
To overcome the confounding effects of hypoglycemia induced by 
administration of insulin, hyperinsulinemic-euglycemic clamps have been useful 
over the last 30 years as an in vivo model to examine whole body insulin sensitivity. 
First described in human subjects (DeFronzo et al., 1979), the concept of increasing 
circulating insulin concentrations using a constant insulin infusion rate with 
concurrent glucose infusion at a varied rate to maintain euglycemia has become the 
gold standard method for examining whole-body responses to insulin. 
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In lactating dairy cows, one of the fi rst experiments using the 
hyperinsulinemic-euglycemic clamp technique was carried out to evaluate the effect of 
insulin on milk synthesis (McGuire et al., 1995b) and components of the insulin-like 
growth factor system (McGuire et al., 1995a). During the 4-d clamp period in which 
circulating insulin concentrations were elevated more than fi ve-fold above baseline 
concentrations, McGuire and coworkers observed a 0.07 kg/d increase in milk protein 
yield, representing a 7% increase in milk protein output during the clamp period. In 
a subsequent experiment from the same group at Cornell University, Griinari et al., 
(1997a; 1997b) used the clamp technique in mid-lactation cows to elevate circulating 
insulin concentrations four-fold above baseline in conjunction with abomasal infusion 
of casein. The combination of insulin administration and casein infusion increased 
milk protein yield by 0.23 kg/d, or 28% above baseline. With provision of additional 
protein substrate in the abomasum in the form of casein and amino acids, (Mackle et 
al., 1999) observed a 25% increase in milk protein output under hyperinsulinemic-
euglycemic clamp conditions that was accompanied by a decrease in circulating 
essential amino acid concentrations, increased mammary blood fl ow, increased 
extraction effi ciency of amino acids, and increased glucose uptake (Mackle et al., 
2000). These results suggest that maximal milk protein production by the mammary 
gland has not been fully reached within typical nutritional management. Furthermore, 
it appears that the hyperinsulinemic-euglycemic clamp alters mammary gland uptake 
and metabolism of protein substrates.
All of the studies referenced above indicate that insulin infl uences mammary 
gland protein synthesis. However, interpretation of results from hyperinsulinemic-
euglycemic clamps is confounded by the co-infusion of both insulin and large amounts 
of exogenous glucose, which makes it diffi cult to determine if the results are due to 
the effects of insulin, glucose, or both. During hyperinsulinemic-euglycemic clamps, 
signifi cant amounts of glucose, and thus energy, are being infused into the cow. In 
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the study by Mackle (1999), the amount of glucose infused per day (3.336 kg) was 
the equivalent of 12.2 Mcal NEL/d (the NEL value used for glucose calculation was 
described by Leonard and Block (1997) as 3.66 Mcal NEL/kg), which is a considerable 
amount of energy.
When administered by itself, insulin is commonly associated with reduced 
milk production and lowered blood glucose. Schmidt (1966) administered short-
acting insulin subcutaneously in primiparous cows and observed an increase in milk 
protein percentage during insulin treatment, but no change in protein yield. Twice-
daily injections of protamine zinc insulin reduced milk yield and blood glucose in 
a study by Kronfeld et al. (1963). As previously mentioned, when given alone, the 
effect of insulin is also confounded by the effect of reduced glycemia. So, regardless 
of how the effects of insulin are investigated, either infused glucose or hypoglycemia 
may confound the results and interpretation. Ideally, the effects of insulin should 
be evaluated in situations without signifi cant changes in glycemia or provision of 
additional glucose.
Numerous insulins and insulin analogues are readily available treatment of 
human diabetes depending on the type and severity of the diabetes, the time of day or 
timing of last meal, and other varying factors (Sheldon et al., 2009). Commercially-
available insulins and insulin analogues come in rapid-acting, intermediate-acting, 
and long-acting formulations. Intermediate and long-acting insulins provide a more 
prolonged release of insulin following injection. These types of slow-release insulin 
have the potential to be used in dairy cows to study the effects of modestly elevated 
insulin activity without the negative effect of severe hypoglycemia.
The use of slow-release insulin in lactating dairy cattle has been limited. 
Hayirli et al. (2002) administered varying doses of protamine zinc insulin (Humulin, 
Ultralente human insulin rDNA origin in extended zinc suspension) via intramuscular 
injection to early lactation cows on d 3 postpartum. Increasing doses of slow-
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release insulin tended to increase milk yield in the early lactation cows, with cows 
receiving a dose of 0.14 IU/kg BW yielding 4 kg/d more from d 3 to 5 postpartum 
than controls. The quadratic effect of increased milk yield may have been due to 
a quadratic increase in DMI. A once daily injection of 0.14 IU/kg BW resulted in 
serum insulin concentrations that were 1.75 times higher than the control in the fi rst 
24 h after injection. Meanwhile, circulating glucose concentrations were 5.2 mg/dl 
lower for the 0.14 dose. Effects of slow-release insulin on plasma glucose and insulin 
were diminished by 24 h after the fi rst injection. In a previous study, we examined 
the 24-h profi le of plasma glucose following a single subcutaneous injection of 0, 0.1, 
0.2 or 0.4 IU/kg BW of either Humulin-N or insulin glargine in lactating dairy cows 
(Winkelman et al., 2010). Increasing doses of both forms of slow-release insulin caused 
linear decreases in plasma glucose concentrations and there were no effects on dry 
matter intake (DMI) during the day of study.
Insulin and other hormones have been reported to regulate initiation of 
protein synthesis in multiple cell culture systems and lactating dairy cow experiments 
(Hayashi et al., 2009; Toerien et al., 2010; Burgos and Cant, 2010; Burgos et 
al., 2010). Insulin may exert its effects on milk protein synthesis, observed in 
hyperinsulinemic-euglycemic clamp studies (e.g. Griinari et al., 1997a; Mackle et 
al., 1999), by activation of the mammalian target of rapamycin (mTOR) signaling 
cascade (Campbell et al., 1999; Proud, 2006; Proud, 2007). The roles of insulin 
and amino acids as they interact with mTOR signaling in the lactating dairy cow 
mammary gland has been examined to some extent (Rius et al., 2010), but are not 
fully understood.
The objective of the present study was to evaluate the effects of two different 
forms of slow-release insulin, Humulin-N and insulin glargine, on milk yield and 
composition by lactating dairy cows over a 10-d treatment period. It was hypothesized 
that milk protein content and yield would be increased by treatment with both types 
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of slow-release insulin. As Mackle et al., (1999) observed changes in milk protein 
production after 4 d using the hyperinsulinemic-euglycemic clamp, we expected that 
any changes in milk yield or composition would occur no later than 10 d after the 
start of treatments. Additionally, it was hypothesized that changes in milk protein 
and component synthesis would be the result of stimulation of the insulin and mTOR 
signaling pathways.
MATERIALS AND METHODS
Animals, Experimental Design, and Treatments
The Cornell University Institutional Animal Care and Use Committee 
approved all procedures involving animals prior to the onset of the experiment. 
Thirty multiparous Holstein cows ranging from 52 to 130 days in milk (DIM; 88 ± 25 
DIM, X ± SD) at the onset of the experiment were blocked into two groups. Within 
each group, cows were assigned randomly to one of three treatments, with an aim to 
balance for DIM and average daily milk yield across all treatments prior to the start 
of the experiment. Treatments consisted of control (C), 0.2 IU/kg BW Humulin-N (H; 
100 IU/ml human insulin [rDNA origin] isophane suspension, Eli Lilly, Indianapolis, 
IN), and 0.2 IU/kg BW Lantus (L; 100 IU/ml insulin glargine [rDNA origin], 
Sanofi -Aventis, Bridgewater, NJ). The H and L treatments were given 2x/day via 
subcutaneous injection, thus resulting in a total daily dose of 0.4 IU/kg BW for both 
treatments. 
Beginning at least 7 d prior to the onset of the experiment, cows were fed a 
common total mixed ration (TMR) formulated using the Cornell Net Carbohydrate and 
Protein System version 6.1 (Tylutki et al., 2008) and designed to provide metabolizable 
protein and Met and Lys in excess of requirements (Table 4-1). Cows were offered a 
common TMR daily at 0900 h and orts were removed before feeding. Amounts of 
feed offered and refused were measured on a daily basis, and samples of the TMR 
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Table 4-1. Dietary ingredients and nutrient composition 
of the basal diet (DM basis)
Ingredient, % Content
Corn silage 46.7
Ground corn 15.5
Wheat straw 6.9
Corn germ meal 5.2
Corn distillers 5.2
Canola meal 5.1
Amino Plus1 4.7
Minerals and vitamins2 3.0
Soybean meal 1.7
Blood meal 1.6
Citrus pulp, dry 1.6
Energy Booster 3 1.1
Molasses 0.7
AminoShure-L4 0.5
Urea 0.3
Alimet5 0.1
Smartamine-M6 0.1
Energy and nutrients7
NEL, Mcal/kg 1.63
NDF 33.0
NFC 41.6
Starch 29.1
Crude fat 4.5
ME allowable milk,8 kg/d 47.0
MP allowable milk,8 kg/d 49.2
MP supply,8g/d 3,255
Lys,8 % of MP 7.33
Met,8 % of MP 2.54
CP 16.3
Lignin 2.7
Calcium 0.59
Phosphorus 0.39
Potassium 1.15
Magnesium 0.27
1 Ag Processing, Inc., Omaha, NE
2 Contained 2.80% Ca, 0.59% P, 0.49% S, 0.65% Mg, 1.40% K, 1.87% NaCl, 68 
mg/kg of Cu, 6 mg/kg of I, 569 mg/kg Zn, 1 mg/kg Se, 30 IU/g Vitamin A, 116 
IU/kg Vitamin E.
3 Prilled saturated FFA, MS Specialty Nutrition, Dundee, IL.
4 AminoShure L was a gift of Balchem Corporation, New Hampton, NY
5 An 88% aqueous solution of dl, 2-hydroxy-4-(methylthio) butanoic acid, Novus 
International, Inc., St. Louis, MO
6 Rumen-protected methionine (>70% DL-methionine, wt/wt), Adisseo USA, 
Alpharetta, GA.
7 Values represent average of 3 weekly feed ingredient and TMR samples 
composited into one sample for analysis. The resulting analysis was inputted into 
the Cornell Net Carbohydrate and Protein System.
8 Cornell Net Carbohydrate and Protein System predicted values based on feedstuff 
composition and a DMI of 26.26 kg/d.
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were collected once each week and dried at 55°C until static weight was reached 
for measurement of dry matter (DM) content. Daily DMI were calculated for each 
cow using the respective amounts of feed consumed and the appropriate weekly DM 
content of the TMR. Samples of the TMR were sent to Cumberland Valley Analytical 
Services (Maugansville, MD) for analysis using wet chemistry techniques for crude 
protein (CP) (AOAC, 2000), acid detergent insoluble CP [CP determined using AOAC 
(2000) after acid detergent extraction (AOAC, 2000)], neutral detergent insoluble CP 
[AOAC (2000) method for CP after neutral detergent extraction (Van Soest et al., 
1991)], soluble CP, (Krishnamoorthy et al., 1982), ADF (AOAC, 2000), NDF (AOAC, 
2000), lignin (Goering and Van Soest, 1970), starch (Hall, 2009), sugar (Dubois et al., 
1956), ether extract (AOAC, 2000), and ash (AOAC, 2000). Chemical composition of 
the basal TMR based on the composition of the components is reported in Table 4-1. 
Individual feed ingredients were also dried, sampled weekly, and analyzed in the same 
manner as the TMR described above. During the experiment, free choice water was 
available at all times.
Cows were weighed twice before the experiment commenced and the average 
weight was used to calculate daily dose of slow-release insulin. Covariate data and 
samples were collected prior to fi rst treatment dose for all cows and included blood 
samples, DMI, and milk yield. Treatments were administered for 10 d at 12-h intervals 
beginning after milking on d 1. Blood samples were taken twice daily via coccygeal 
venipuncture into evacuated tubes containing sodium heparin (Vacutainer, Becton 
Dickinson, Franklin Lakes, NJ) immediately prior to the 1000 h dose and again at 
1600 h. Samples were placed on ice until centrifugation (3,000 x g for 20 min at 4ºC) 
and separation of plasma. Plasma samples were quickly frozen in liquid N and stored 
at -20ºC until further analysis. 
Cows were milked twice daily at 0900 and 2100 h and milk yields were 
recorded at each milking. Milk samples were collected during each milking one day 
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prior to the onset of treatment and on d 2, 4, 6, 8 and 10 of the experiment and stored 
at 4°C with a preservative (2-bromo-2-nitro-1,3-propanediol) until analyzed (Dairy 
One Cooperative Inc., Ithaca, NY) for fat, true protein, and lactose using infrared 
analysis (AOAC, 2000; method 972.160), somatic cell count (SCC) by an optical 
fl uorescent method (AOAC, 2000; method 978.26), and milk urea nitrogen (MUN). 
Energy-corrected milk (ECM) yield was calculated using the following equation from 
DHI: ECM, kg/d = (0.327 x milk kg) + (12.95 x fat kg) + (7.65 x protein kg) (Dairy 
Records Management Systems, 2011).
Additionally, composite milk samples from the covariate period, representing 
one day’s milk by weighted volume, and from d 10 were analyzed for milk nitrogen 
fractions. Casein was determined by the indirect method (Lynch et al., 1998) such that 
casein was precipitated at pH 4.6 in acetic acid and sodium acetate, and noncasein 
N (NCN) in the fi ltrate was measured by Kjeldahl nitrogen analysis. Total nitrogen 
(TN) of the sample was also measured by Kjeldahl analysis (Barbano et al., 1990). The 
amount of casein (N x 6.38) in the sample was calculated as the difference between 
the amount of TN and NCN. To determine nonprotein nitrogen (NPN), proteins were 
precipitated and fi ltered from the sample by addition of 12% (wt.:vol.) trichloroacetic 
acid (Barbano et al., 1991). The nitrogen content of the fi ltrate, as measured by 
Kjeldahl nitrogen analysis, is the NPN (N x 6.38) fraction. The amount of true protein 
can be calculated by difference taking the difference between TN and NPN (N x 6.38).
Mammary Biopsies
On d 11, 12 to 15 h following the last treatment injection and 1 to 3 h after 
the morning milking, samples of mammary tissue were obtained by biopsy of the 
right hind quarter of all cows on the experiment. Xylazine was administered in the 
coccygeal vein (15 to 25 mg) to aid in animal handling during the procedure. The 
area to be biopsied on the right rear quarter of the mammary gland was aseptically 
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prepared with betadine and 70% ethyl alcohol. Local anesthetic (15 ml of 2% lidocane) 
was given under the skin at the biopsy site. A size 22 scalpel blade was used to cut 
an approximately 0.5 cm incision in the skin. A Bard Magnum trocar (12 gauge, 16 
cm length) was inserted approximately 5 cm into the incision site reaching mammary 
tissue. The trocar was placed further into the mammary gland at three different 
sites and biopsy cores were obtained using the Bard Magnum Biopsy System and 
Bard TruGuide Coaxial Biopsy Needle (Bard, Covington, Georgia). Biopsy cores from 
each site were placed in aluminum foil packets, quickly frozen in liquid N, and stored 
at -80ºC until further analysis. After completion of biopsy core collection, sterile 
gauze was held on the biopsy site until bleeding ceased. If bleeding did not cease after 
pressure had been applied, super glue was used to close the incision site. Only 1 cow 
required the use of super glue to stop bleeding at the incision site. One cow developed 
mastitis after the biopsy due to diffi culty in removing milk from the biopsied quarter. 
No noticeable declines in milk yield or DMI were observed in the remaining cows in 
the 7 d following the biopsy.
Mammary Protein Extraction and Western Blotting
Mammary proteins were extracted from the biopsy samples taken on d 11. 
Briefl y, approximately 50 mg of tissue was homogenized on ice in 400 μl of cold lysis 
buffer containing 10 mmol/L Tris pH 7.5, 10 ml/L Triton X-100, 1 mmol/L EGTA, 
150 mmol/L NaCl, and a protease and phosphatase inhibitor cocktail (#78441 Halt 
Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100X), Thermo Scientifi c, 
Rockford, IL). Protein concentration of the resulting supernatant was determined by 
the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology Inc., Rockford, IL). 
Supernatants were stored at -80ºC until electrophoresis.
Protein lysate supernatant was diluted in equal volumes with Laemmli 
SDS sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 10% 
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β-mercaptoethanol, and 0.004% bromophenol blue) and boiled for 5 minutes. 
Approximately 20 μg of protein was loaded onto 10% discontinuous polyacrylamide 
gels and electrophoretically separated until sample dye neared the bottom of 
the separating gels, approximately 90 minutes at 144 V (SE 260 Mighty Small 
Unit, Hoefer, Inc., Holliston, MA). Polyvinylidene fl uoride (PVDF) membranes 
(Amersham Hybond-P, GE Healthcare, Fairfi eld, CT) were prepared for protein 
transfer by pre-wetting in 100% methanol for 1 to 2 seconds and then soaking in 
transfer buffer for approximately 15 minutes. Transfer cassettes were assembled 
and proteins were transferred from the gel to the pre-wetted membrane in a tank 
transfer system (TE 22 Mini Transfer Tank, Hoefer, Inc., Holliston, MA). Transfer 
was carried out at 22 V for 2 hours at room temperature. After transfer, membranes 
were rinsed with Tris-buffered saline containing 0.1% Tween (TBS-T) two times and 
non-specifi c binding sites were blocked for 1 h at room temperature using 2% (wt/
vol) blocking reagent in TBS-T (ECL Advance Blocking Reagent, GE Healthcare, 
Fairfi eld, CT). Membranes were incubated with phospho-specifi c primary antibodies 
overnight at 4ºC. Membranes were washed 5x in TBS-T and incubated with 
secondary antibody in TBS-T containing 2% blocking reagent for 1 h at room 
temperature. Membranes were again washed 5x in TBS-T before incubation with 
chemiluminescence reagents.
Immunoreactive proteins were detected by enhanced chemiluminescence 
(Lumigen TMA-6, in the ECL Advance Western Blotting Kit, GE Healthcare, 
Fairfi eld, CT) by exposing the membranes to x-ray fi lm (Amersham Hyperfi lm ECL, 
GE Healthcare, Fairfi eld, CT), with varying exposure times to obtain detectable and 
measureable signal. The images on the fi lm were analyzed for densitometry by NIH 
Image/J Software (http://rsb.info.nih.gov/ij/).
After detection of phospho-specifi c signals, the antibodies were stripped off 
of the membrane by incubation with stripping buffer (62.5 mM Tris-HCl, 100 mM 
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β-mercaptoethanol, and 2% SDS) at 55ºC for 30 minutes and washed with TBS-T 
before re-blocking and probing for total protein. All primary antibodies were obtained 
from Cell Signaling Technology (Beverly, MA) and were diluted as follows: anti-
phospho-Akt (Ser 473) – 1:50,000, anti-Akt (total) – 1:20,000, anti-phospho-ribosomal 
protein S6 (rpS6) (Ser 235/236) – 1:50,000, anti-rpS6 (total) – 1:20,000. Secondary 
antibody (GE Healthcare, Fairfi eld, CT) was diluted 1:200,000. The densities of the 
phosphorylated signals were normalized to total protein levels.
Plasma Hormone and Metabolite Analysis
Plasma concentrations of glucose were determined by enzymatic analysis 
(glucose oxidase) using a commercially-available reagents (#P7119 PGO Enzyme 
Preparation, #F5803 3,3’Dimethoxy benzidine dihydrochloride; Sigma Aldrich, St. 
Louis, MO). Intra-assay and interassay coeffi cients of variation (CV) for glucose 
analysis were 2.6 and 3.3%, respectively. Plasma urea nitrogen was measured by the 
hypochlorite-phenol nitroprusside method using a commercially available enzymes 
and reagents (#U3383 Urease Buffer Reagent, #P6994 Phenol Nitroprusside solution, 
#A1727 Alkaline Hypochlorite solution; Sigma Aldrich, St. Louis, MO). Intra-
assay and interassay coeffi cients of variation for PUN analysis were less than 4 and 
7%, respectively. Additionally, plasma concentrations of NEFA were analyzed by 
enzymatic analysis (NEFA-C; Wako Pure Chemical Industries, Osaka, Japan). Intra-
assay and interassay coeffi cients of variation for NEFA analysis were less than 3 and 5 
percent, respectively. Spectrophotometric readings were made using a Versamax tunable 
microplate reader (Molecular Devices, Sunnyvale, CA). Plasma insulin concentration 
was determined by a commercially available radioimmunoassay (RIA) kit which 
has 90% cross-reactivity with native bovine insulin (#PI-12K Porcine Insulin 
Radioimmunoassay, LINCO Research, St. Charles, MO). Intra-assay and interassay 
CV for the RIA insulin analysis were both 10%. 
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Statistical Analysis
One cow was removed from the experiment on d 5 due to potential 
complications from insulin glargine treatment confounded by an injury to the left 
front leg. Thus data from d 1 to 4 represent 30 cows, while for d 5 through 10, only 
29 cows are included in the data set. For plasma analysis, the MIXED procedure of 
SAS (SAS Institute, 2001) was used and included multivariate repeated measures to 
account for the nested sampling scheme of two plasma samples collected within each d 
for 10 d. The model included the main effects of treatment, day, time of sampling, and 
all of the associated two- and three-way interactions. For daily DMI and milk yield, 
the statistical model included the fi xed effects of treatment, day, and the interaction of 
treatment x day. For the variables measured daily, multiple covariance structures were 
tested and the structure yielding the smallest Akaike’s Information Criterion value was 
selected. For the tissue biopsy and western blot statistical analysis, the model included 
the effect of treatment. Protein yield prior to the start of treatments was included as 
a covariate. Pretreatment values for DMI, milk yield, and plasma variables measured 
or assessed during the week before assignment to treatments were used as covariates 
during analysis of covariance for their respective analyses.
RESULTS AND DISCUSSION
The nutrient composition of the TMR is presented in Table 4-1. As designed, 
the diet contained excess metabolizable protein and supplemental Met and Lys to 
ensure that enough substrate would be available for protein synthesis if the cows 
responded to slow-release insulin treatments. Based on mean DMI (Table 4-2) for 
each treatment and nutrient analyses of the diet ingredient feedstuffs, the Cornell Net 
Carboyhydrate and Protein System (v. 6.1) (Tylutki et al., 2008) predicted the available 
MP supply (unadjusted for maintenance MP requirements) to be 3,273 g/d for C, 3,247 
g/d for cows treated with H, and 3,327 g/d for cows treated with L.
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DMI, Milk Yield, and Milk Composition
Production results are presented in Table 4-2. Dry matter intake, milk yield, 
and ECM did not differ between treatments (P > 0.05). In multiple experiments, 
Kronfeld et al. (1963) administered protamine zinc insulin, another form of slow-
release insulin, intramuscularly twice daily at various doses to cows. In one of the 
experiments, fi ve successive doses of 0.24 U/kg, which was similar to the dose used 
in the present experiment, had little effect on plasma glucose or milk production. 
When the insulin dose was increased two-fold, both milk yield and plasma glucose 
concentrations were decreased markedly (Kronfeld et al., 1963). Though this part 
of the experiment by Kronfeld et al. (1963) only had one animal, it supports the 
observations of the present experiment showing moderate doses of slow-release insulin 
have little to no effect on milk yield. On the other hand, it appears that higher doses of 
insulin have greater impact on milk yield and dry matter intake. Cows given regular 
insulin at a dose of 0.3 U/kg BW (Schmidt, 1966) after each milking showed decreased 
milk production during the treatment period and signs of hypoglycemia three days 
after the starting treatment. In the experiments by Kronfeld et al. (1963) with higher 
doses of insulin, numerous cows became recumbent and depressed during treatment 
with successive doses of insulin, and during these severe hypoglycemic episodes, the 
authors report that the cows did not eat. Hypoglycemia, as opposed to insulin itself, 
was likely the cause of reduced milk yield, as restoration of normal plasma glucose 
concentrations by exogenous glucose administration in cows treated with insulin 
also restored milk production (Kronfeld et al., 1963). Maintenance of milk yield is 
commonly observed during hyperinsulinemic-euglycemic clamps (McGuire et al., 
1995b; Mackle et al., 1999), which further supports the concept that hypoglycemia is 
the cause of reduced milk yield when insulin is administered at large doses.
There was a tendency for increased milk fat content and yield with slow-release 
insulin treatment (P = 0.12 and P = 0.13 for milk fat content and yield, respectively, 
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Table 4-2). The tendency for a treatment difference appears to be driven largely by 
the 10% increase in fat content and yield in cows treated with L (contrast C vs. L, P < 
0.05), as there was no effect of H on milk fat content (P = 0.36) or yield (P = 0.44). The 
increase in milk fat production for cows treated with L was unexpected as studies with 
hyperinsulinemic-euglycemic clamps have reported no change (McGuire et al., 1995b) 
or a decrease in milk fat content (Griinari et al., 1997b; Mackle et al., 1999; Bequette et 
al., 2001; Corl et al., 2006). Similarly, in study by Leonard and Block (1997), milk fat 
content and yield were reduced by 15 and 21%, respectively, in cows treated with both 
insulin and glucose compared to saline-infused control cows. During close arterial 
infusion of insulin to the mammary gland, a non-signifi cant increase in milk fat yield 
was observed (Metcalf et al., 1991). In the present study, it is unclear why cows treated 
with L had higher milk fat yield. Though insulin does not regulate glucose uptake by 
the mammary gland, mammary epithelial cells exhibit responsiveness to insulin. The 
discrepancy between the lack of response of cows treated with H compared to the 
response by cows treated with L may be related to the altered amino acid structure 
of H relative to L (Owens and Bolli, 2008). As L is an analogue of insulin, the amino 
acid substitutions to the molecule may alter its insulin receptor affi nity and residence 
time or make the analogue have greater affi nity for receptors of the insulin-like growth 
factor family (Kurtzhals et al., 2000; Staiger et al., 2007; Shukla et al., 2009).
Milk protein content and yield were both affected by administration of slow-
release insulin (Table 4-2). A treatment by day interaction was observed for milk 
protein yield such that responses to treatment increased over the 10-d treatment period 
(Figure 4-1). Though milk protein content for cows treated with H was 6.7% higher 
than control cows, milk protein yield did not differ between those two treatments. On 
the other hand, milk protein content and yield were 9.6 and 5.5% higher, respectively, 
for cows treated with L when compared to control cows. A possible explanation for the 
greater response in protein yield by cows treated with L may be related to the overall 
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Figure 4-1. Milk protein yield, kg/d, for control cows (–●–), cows treated twice daily 
with 0.2 IU/kg BW of Humulin-N (–■–), or cows treated twice daily with 0.2 IU/kg 
BW of insulin glargine (–▲–) treatments. Treatments were given by subcutaneous 
injection at 1000 h and 2200 h for 10 d. Values shown are the least square means and 
their associated standard errors. Probabilities of significance for effects of treatment, 
day, and treatment x day interaction were P = 0.084, P = 0.001, and P = 0.076, 
respectively.
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Figure 4-2. Milk urea nitrogen, mg/dl, for control cows (–●–), cows treated twice 
daily with 0.2 IU/kg BW of Humulin-N (–■–), or cows treated twice daily with 0.2 IU/
kg BW of insulin glargine (–▲–) treatments. Treatments were given by subcutaneous 
injection at 1000 h and 2200 h for 10 d. Values shown are the least square means and 
their associated standard errors. Probabilities of significance for effects of treatment, 
day, and treatment x day interaction were P = 0.012, P < 0.001, and P = 0.076, 
respectively.
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amount of insulin-activity in these cows. Based on plasma glucose concentrations, 
it would appear that cows treated with L had higher insulin activity during the 10-
d treatment period as evidenced by lower plasma glucose than cows treated with H. 
Milk urea nitrogen concentrations were decreased by administration of both forms of 
slow-release insulin and least square means for MUN were 13.5, 12.5, and 12.3 ± 0.52 
mg/dl for C, H, and L treatments, respectively. A treatment by day interaction was 
observed for MUN (P = 0.076) and this interaction is shown in Figure 4-2. Lowered 
MUN concentrations suggest greater effi ciency of use of N in cows treated with slow-
release insulin. Using the means for protein yield and DMI, and estimated MP supply, 
the effi ciency of MP use for milk protein was 0.446, 0.459, and 0.463 g of true milk 
protein per g of MP for the control, H, and L treatments, respectively. These values are 
lower than those reported by Metcalf et al., (2008) and the values reported by Metcalf 
et al., include a correction for MP maintenance requirements. If the present data are 
adjusted for the amount of MP used for maintenance, the effi ciency of MP use for milk 
protein becomes 0.626, 0.644, and 0.649 g of true milk protein per g of MP for the 
C, H, and L treatments, respectively, which are much closer to the effi ciency values 
reported by Metcalf and coworkers (2008) of 0.62 to 0.64.
In this experiment, lactose content and yield were reduced by treatment (P = 
0.001 and P = 0.07, for content and yield, respectively) with both slow-release insulins. 
For cows treated with H, lactose content was reduced by 1.7% (P = 0.02), while yield 
had a tendency to be reduced by 3.4% (P = 0.13) when compared to control cows. For 
cows treated with L, the reduction in lactose content was 2.9% (P < 0.001) and the 
reduction in yield was 5.6% (P = 0.02) versus control cows. As lactose is considered 
to be the major osmoregulator of milk and thus dictates milk volume, these signifi cant 
reductions in milk lactose yield may be the explanatory variable behind the non-
signifi cant, but numerical declines in milk yield for cows treated with both slow-
release insulin types. In the series of experiments by Schmidt (1966), insulin injections 
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also resulted in reduced lactose content and yield. Similarly, cows given insulin and 
glucose (Leonard and Block, 1997) in early lactation also had reduced milk lactose 
yield. Rook et al. (1965) observed that when plasma glucose fell below 40 mg/dl, 
milk yield and lactose yield dramatically decreased, suggesting a baseline need for 
plasma glucose in total lactose yield. Though glucose is the main substrate for lactose 
synthesis, it does not appear to be the only driver for lactose synthesis as studies using 
phlorizin to increase glucose disposal in the urine have shown no change in lactose 
synthesis in lactating dairy cows (Amaral-Phillips et al., 1993; Bradford and Allen, 
2007). However, plasma glucose concentrations in these studies were only reduced 
nominally despite large quantities of urinary glucose disposal. Work by Bradford 
and Allen (2005) in late lactation cows suggests that cows at this stage of lactation 
have suffi cient gluconeogenic capacity in the liver to overcome the phlorizin-induced 
glucose defi cit.
Table 4-3. Effect of twice-daily subcutaneous injections of two types of slow-release 
insulin on milk nitrogen fractions and protein composition for composite milk samples 
collected on day 10 of treatment
Treatment1   P-value
Variable C H L SEM2 Trt C vs. H C vs. L
CP,3 % 3.17 3.36 3.41 0.146 0.006 0.013 0.003
CP, kg/d 1.53 1.57 1.66 0.116 0.070 0.455 0.027
NCN,4 % 0.69 0.72 0.75 0.031 0.006 0.058 0.002
NCN, kg/d 0.33 0.34 0.36 0.024 0.111 0.480 0.044
NPN, 4 % 0.18 0.17 0.18 0.01 0.761 0.607 0.855
NPN, kg/d 0.09 0.08 0.09 0.01 0.591 0.511 0.759
True Protein,5 % 3.00 3.19 3.22 0.14 0.003 0.007 0.002
True Protein, kg/d 1.44 1.49 1.58 0.11 0.057 0.397 0.021
Casein, 6 % 2.49 2.63 2.65 0.124 0.019 0.020 0.012
Casein, kg/d 1.20 1.23 1.30 0.094 0.069 0.446 0.026
Casein, % of True Protein 82.8 82.6 82.5 0.64  0.696 0.462 0.465
1 Treatments: C = control, H = 0.2 IU/kg BW Humulin-N, L = 0.2 IU/kg BW insulin glargine given twice daily via subcutaneous 
injection at 1000 h and 2200 h.
2 SEM = standard error of the mean.
3 Crude protein is equal to total nitrogen (TN) x 6.38.
4 Both NPN and NCN are multiplied by 6.38 to allow comparison with other protein fractions.
5 True protein is calculated as (TN - NPN) x 6.38.
6 Casein protein is calculated as (TN - NCN) x 6.38.
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Cows treated with L had 4% higher total solids content in their milk compared to 
control cows (P = 0.024; Table 4-2). There was no difference between cows treated with 
H and control animals (P > 0.05). However, with the non-signifi cant reduction in milk 
yield for cows treated with L, there was no difference in total solids yield by treatment 
and this was also observed with no effects of treatment on energy-corrected milk yield 
(Table 4-2). Somatic cell counts in milk were not affected by treatment (P > 0.05). 
Milk Nitrogen Fractions and Protein Composition
Milk nitrogen fractions and protein composition are presented in Table 4-3. 
Crude protein, as equal to the total N content of the milk multiplied by 6.38, was 
increased by treatment with slow-release insulin. Crude protein content was 6% 
higher for cows treated with H and 7.6% higher for cows treated with L compared 
to control cows. Crude protein yield was 8.5% higher for cows treated with L 
compared to control cows, but crude protein yield for cows treated with H did 
not differ from controls. True protein, as reported in Table 4-3, was calculated by 
subtracting NPN from TN and multiplying by 6.38. True protein content was 6.3 
and 7.3% higher for cows treated with H and L, respectively, and the TP yield was 
9.7% higher for cows treated with L. The mean TP content for each treatment, as 
determined by Kjeldahl analysis, were as follows: 3.00, 3.19, and 3.22 ± 0.14 for C, 
H, and L, respectively.
The TP content and yields determined by this method correlate well with the 
TP values reported in Table 4-2, which were determined by Dairy One Cooperative, 
Inc. (Ithaca, NY) by mid-infrared spectroscopy. Slight differences could be expected 
between these two TP values as the values in Table 4-2 from Dairy One represent 
samples taken twice per day on every other day of the treatment period, while the 
values reported in Table 4-3 are the results from a composite sample of the 2 milking 
times collected only on d 10 of the study. 
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Casein content of the milk was increased by treatment with slow-release 
insulin and was about 6% higher for cows treated with either H or L compared to 
controls. Casein yield was 8.3% higher for cows treated with L (P = 0.01) when 
compared to controls, but yield from cows treated with H was not different from that 
of the control cows (P = 0.45). Though there was an increase in the casein content of 
the milk for cows treated with both forms of slow-release insulin, the composition 
of the major milk proteins was not affected by treatment (P = 0.70) as the casein 
percentage of true protein was maintained near 82.5% for all treatments. Under 
hyperinsulinemic-euglycemic clamp conditions, other studies have also observed no 
change in the composition of the major milk proteins (Griinari et al., 1997a; Mackle et 
al., 1999).
Noncasein nitrogen content increased with treatment of both H and L, and 
the response was greater for L (Table 4-3). Additionally, the yield of NCN tended to 
be higher by treatment (P = 0.111). Nonprotein nitrogen content and yield were not 
affected by treatment with either form of slow-release insulin (P > 0.10). Mackle et 
al. (1999) reported similar observations for NCN and NPN under hyperinsulinemic-
euglycemic clamp conditions.
Plasma Hormones and Metabolites 
Results for plasma glucose, NEFA, PUN, and insulin concentrations in 
response to treatment with slow-release insulins are presented in Table 4-4. As 
expected, plasma glucose concentrations were lower for cows treated with either H 
or L when compared to control cows. Cows treated with H had 8.5% lower plasma 
glucose, while cows treated with L had 15.3% lower plasma glucose concentrations. 
The mean plasma glucose concentrations were 56.8, 52.0, and 48.1 ± 0.99 mg/dl for 
C, H, and L, respectively. These results are similar to the decreases observed in our 
dose response study (Winkelman et al., 2010), though those results represent only a 
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24-h sampling period of hourly samples. As with the aforementioned study, there were 
no visually apparent signs of hypoglycemia during the experiment, which suggested 
that cows at this stage of lactation had suffi cient gluconeogenic capacity to adapt their 
glucose homeostasis to the administration of slow-release insulin. However, it would 
be expected that at cows did experience transient states of hypoglycemia throughout 
the day, based on the 95% confi dence intervals around the mean plasma glucose values 
for the 24-h dose response study, as discussed in Chapter 3.
Though there was an overall effect of treatment on plasma NEFA (P = 0.008), 
this difference was driven by 19% higher NEFA in cows treated with H (compared to 
C; P = 0.013), as NEFA were not different between control cows and those treated with 
L (P = 0.23). Although NEFA were higher for cows treated with H, the concentrations 
observed are within normal physiological range for cows at this stage of lactation. 
Increased plasma NEFA concentrations were not expected for either of the slow-release 
insulin treatments because insulin suppresses lipolysis and promotes lipogenesis in 
adipose tissue (Brockman, 1978). Recall that milk fat content and yield were higher 
for cows treated with L, but not statistically different for H. This observation, in 
combination with no change in plasma NEFA concentration for cows treated with L, 
suggests that de novo synthesis of milk fatty acids was stimulated by treatment with 
L, but not H. If this theory is true, the proportion of medium and short-chain fatty 
acids in milk would be higher for cows treated with L (Palmquist et al., 1993) and may 
account for the difference in milk fat output observed here. 
Plasma urea nitrogen concentrations were affected by treatment (P < 0.01), 
and this observation was largely driven by treatment with L as PUN concentrations 
were 8% lower in cows treated with L as compared to control cows. Plasma urea 
nitrogen concentrations over the 10-d treatment period were 11.4, 11.2, and 10.5 ± 0.49 
mg/dl for C, H, and L treatments, respectively. Under the experimental context of the 
hyperinsulinemic-euglycemic clamp when cows produced 15% more milk protein, 
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PUN concentrations were 31.5% lower than control animals (Mackle et al., 1999). 
As blood urea rapidly equilibrates with milk urea (Gustafsson and Palmquist, 1993), 
the reduction in PUN observed here corresponds with the nearly 9% reduction in 
MUN (Table 4-2), improved milk protein yield, and incremental improvement in the 
conversion of MP into milk protein.
Plasma insulin concentrations as measured by RIA were higher for cows 
treated with either H or L. Due to challenges in measuring L and its metabolites in 
plasma (Winkelman et al., 2010 and discussed in Chapter 3), the values for cows 
treated with L may not be completely indicative of overall insulin activity within these 
cows. Regardless, as plasma glucose concentrations were lower in all cows treated 
with either form of slow-release insulin, we can reasonably state that insulin-like 
activity was elevated in cows treated with H and L.
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Figure 4-3. Effect of twice-daily subcutaneous injections of two different slow-
release insulins on signaling molecules in the mammary gland. Treatments consisted 
of control (C), and treatment with either Humulin-N (H) or insulin glargine (L) at 
a dosage rate of 0.2 IU/kg BW twice daily at 12-h intervals for a total daily dose of 
0.4 IU/kg BW. Bars represent least-square means (± SEM) of phosphorylated to total 
relative abundance ratios of arbitrary density units. Treatment affected the ratio of 
phosphorylated to total Akt (P = 0.05) and was highest for H. There was no effect of 
treatment on the ratio of phosphorylated to total ribosomal protein S6 (rpS6; P = 0.60).
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Cell Signaling
The ratio of phosphorylated to total abundance of Akt and rpS6 are shown in 
Figure 4-3. Treatment affected the phosphorylation ratio of Akt (P = 0.05), but not rpS6 
(P = 0.60). Cows treated with H had the highest phosphorylation state of Akt. Because 
no changes in the signaling molecule downstream of mTOR (rpS6) were observed in the 
lysates, no further analysis was completed on the mammary protein lysates. The actual 
western blot images used in densitometry analysis can be found in the Appendix.
There are a few reasons why no detectable or more signifi cant differences in 
these signaling components were observed in the present study. First, the amount of 
time (12 to 15 h) that passed between the last treatment dose and the time of biopsy 
may have been longer than optimal to evaluate changes in phosphorylation state of 
these proteins. Changes in phosphorylation state occur rapidly, within minutes after 
stimulation, (Bolster et al., 2004; Burgos and Cant, 2010), thus the biopsies taken in 
this study would have missed the acute changes in phosphorylation status of these 
proteins. However, as both H and L have extended duration of action, we thought the 
changes in phosphorylation of these proteins may have been observable at the time of 
the biopsy. In addition to acute changes to stimulate protein synthesis, insulin exerts 
a longer term effect by increasing the capacity for protein synthesis by increasing the 
number of ribosomes (Bolster et al., 2004; Proud, 2006; Mahoney et al., 2009). By the 
time the mammary biopsies were taken on d 11, it would be possible that changes in 
phosphorylation state of Akt and rpS6 by 12 to 15 h post-insulin treatment would be 
masked by a greater overall capacity of the tissue to synthesize proteins such that the 
phosphorylation ratios would not be different.
Additionally, biopsies were taken relatively soon after milk removal (within 3 
h post milking). The respiratory quotient of the mammary gland is highest during the 
fi rst 6 h following milk removal (Thivierge et al., 2002a), suggesting high conversion of 
nutrients rich in oxygen to products with relatively low oxygen content, such as lipids and 
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proteins. The mammary gland is a tissue of high metabolic activity and protein synthesis 
by the mammary gland accounts for more than 40% of whole-body protein synthesis 
(Thivierge et al., 2002b). With high rates of metabolism and synthesis occurring during 
this period following milking, it would be possible that the protein synthetic machinery 
in the mammary gland was highly active for all the cows at this time and not just the 
cows treated with slow-release insulin. Given these possible explanations for the lack of 
signifi cant changes in the signal transduction proteins evaluated here, it would have been 
ideal to alter the timing of the mammary biopsy to be closer to the time of treatment. 
Additionally, it would have been ideal to have a biopsy collected prior to treatments 
commenced as a covariate point of adjustment in analysis.
CONCLUSIONS
Insulin appears to play a role in milk protein synthesis based on the results 
reported here with the use of slow-release insulin products and confi rms the 
conclusions drawn from studies using hyperinsulinemic-euglycemic clamps in 
lactating cows (Griinari et al., 1997a; Mackle et al., 1999). Using the slow-release 
insulins described here provide an alternative method to study the effects of insulin 
without large decreases in glycemic state or severe hypoglycemia. Further work needs 
to be completed to explain the improvement in milk protein and fat yield reported 
here, but we hypothesize that signaling through the mammalian target of rapamycin 
pathway is altered under elevated insulin activity (Proud, 2006).
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CHAPTER FIVE: EFFECTS OF INSULIN GLARGINE ON MAMMARY 
AMINO ACID UTILIZATION BY LACTATING DAIRY COWS
ABSTRACT
Three multiparous lactating Holstein dairy cows received twice-daily 
subcutaneous injections of insulin glargine (0.15 IU/kg BW per injection, total daily 
dose 0.3 IU/kg BW) or sterile water at 12-h intervals for 4 d in a complete crossover 
design with two periods. Cows were randomized to one of two sequences, either 
insulin treatment followed by control, or control followed by insulin treatment. On d 
4 of the treatment period, simultaneous blood samples were collected from catheters 
inserted in the intercostal artery and subcutaneous abdominal vein at hourly intervals 
for 12-h. Treatment with insulin glargine decreased plasma glucose concentrations 
in both the arterial (P < 0.001) and venous blood supplies (P < 0.001). Mean arterial 
glucose concentrations were 63.1 and 56.9 mg/dl for the control and insulin glargine 
treatment periods, respectively. Mammary blood fl ow was nonsignifi cantly decreased 
during treatment with insulin glargine. Mammary uptake of both essential (P = 
0.059) and nonessential (P = 0.086) amino acids were reduced during insulin glargine 
treatment. No effects of treatment were observed for dry matter intake or most milk 
production variables. Milk yield tended to be lower (P = 0.15) during the insulin 
glargine treatment, but subclinical mastitis in one cow during the insulin glargine 
treatment period may have contributed to this response. Milk lactose content (P = 
0.094) and yield (P = 0.091) decreased with treatment of insulin glargine. Casein 
expressed as a percentage of true protein did not differ between treatments (P = 0.34), 
but noncasein N content was increased by treatment with insulin glargine (P = 0.006). 
Overall these results suggest that insulin glargine altered effi ciency of use of amino 
acids by the mammary gland as evidenced by reduced uptake of both essential and 
nonessential amino acids but no change in milk protein output.
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INTRODUCTION
Milk protein continues to be the most valuable milk component under the 
multiple component pricing system in the dairy industry. Altering diets to improve 
protein yield have had only marginal success (Sutton, 1989), particularly in well-fed 
dairy cows. The use of hyperinsulinemic-euglycemic clamps in lactating dairy cows 
(McGuire et al., 1995; Griinari et al., 1997; Mackle et al., 1999b) has been shown to 
increase milk protein content and yield by up to 28%, suggesting that milk protein yield 
under current management conditions is not maximized. Additionally, the effi ciency 
of converting dietary nitrogen (N) into milk protein output is relatively poor in the 
lactating ruminant, between 25 to 30 percent (Bequette et al., 1998). The conversion 
of metabolizable protein to milk true protein approximates 0.62 to 0.64 g of milk true 
protein per g of metabolizable protein (Metcalf et al., 2008). While conversion of MP 
to productive N is higher than the conversion of dietary N to productive N, there is 
still opportunity to improve N utilization within the ruminant. Improving N effi ciency 
within the cow will help the industry to avoid costly N loss to the environment, as low 
N effi ciency of use leads to greater losses of N in urine (Broderick, 2003). 
During hyperinsulinemic-euglyemic clamp studies in lactating ruminants, 
arterial concentrations of the branched-chain amino acids are decreased (Griinari et 
al., 1997; Mackle et al., 1999b; Mackle et al., 2000), but the extraction effi ciencies of 
these amino acids are increased (Mackle et al., 2000). While these observations are 
attributed to the effects of elevated circulating insulin concentrations, the confounding 
effects of large amounts of glucose, and thus energy (Leonard and Block, 1997), 
may also be playing a role in these changes in amino acid supply and uptake by the 
lactating ruminant mammary gland. Close arterial glucose infusion at the mammary 
gland decreases blood fl ow to the gland (Cant et al., 2002) and therefore it is reasonable 
to assume that glucose infusion during hyperinsulinemic-euglycemic clamps may also 
exerts changes in mammary metabolism and nutrient use by the mammary gland.
93
The goal of the present research was to further defi ne the role of insulin in 
changes in mammary usage of amino acids through use of a form of slow-release insulin 
to modestly increase insulin activity in lactating dairy cows without large changes 
in glycemia. In the present experiment, the slow-release insulin analogue, insulin 
glargine (Lantus, Sanofi -Aventis, Bridgewater, NJ) was used to determine its effects on 
mammary uptake and utilization of amino acids in well-fed lactating dairy cows.
MATERIALS AND METHODS
Animals, Experimental Design, and Treatments
The Cornell University Institutional Animal Care and Use Committee 
approved all procedures involving the dairy cows used in the experiment described 
below. Three multiparous Holstein cows (101 DIM ± 22 d) with indwelling 
intercostal arterial catheters were used in this experiment. The cows with the 
indwelling intercostal arterial catheters were carried over from a previous 
experiment (Hofherr et al., 2010) and the catheter patency was maintained in 
between the end of that aforementioned experiment until the end of present study. 
Experimental design consisted of a complete crossover of treatments with a washout 
period occurring in between periods. Treatment periods lasted 4 d, and the washout 
period was 2 d. 
Cows were offered a common total mixed ration (TMR; Table 5-1) daily at 
0900 h and orts were removed before feeding. The diet was formulated to meet NRC 
recommendations for nutrients (National Research Council, 2001). Amounts of feed 
offered and refused were measured on a daily basis, and samples of the TMR were 
collected daily and dried at 55°C until static weight was reached for measurement of 
DM content. Daily DMI were calculated for each cow using the respective amounts 
of feed consumed and the appropriate daily DM content of the TMR. Samples of 
the TMR were composited within period and sent to Cumberland Valley Analytical 
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Table 5-1. Dietary ingredients and nutrient composition 
of the basal diet (DM basis)
Ingredient, % Content
Corn silage 45.1
Alfalfa silage 14.5
Concentrate mix1 18.1
Concentrate mix2 7.3
Corn meal 7.2
Corn distillers grain 7.2
Energy Booster3 0.6
Energy and nutrients4
NEL, Mcal/kg 1.72
CP, 17.3
Soluble Protein, % CP 45.9
RDP, % CP 73.0
ADF 20.1
NDF 34.2
NFC 38.9
Ash 6.5
Calcium 0.59
Phosphorus 0.40
Magnesium 0.30
Potassium 1.33
Sodium 0.5
Iron, ppm 223
Manganese, ppm 789
Zinc, ppm 101
Copper, ppm 18
1 The concentrate mix was comprised of (DM basis): 27.1% corn germ meal; 16.5% 
citrus pulp, 11.5% wheat midds, 11.6% bakery product, 5.3% cereal tailings, 5.2% 
blood meal, 4.0% molasses, 3.2% soybean meal, 3.4% bypass fat, 2.9% calcium 
carbonate, 2.8% sodium bicarbonate, 1.8% salt, 1.6% urea, 0.9% Optigen II 
(Alltech, Lexington, KY), 0.8% tallow, 0.6% magnesium oxide, 0.3% Alimet (88% 
aqueous solution of dl, 2-hydroxy-4-(methylthio) butanoic acid, Novus Internation-
al, Inc., St. Louis, MO), 0.2% selenium 0.06%, 0.1% trace minerals, 0.1% calcium 
salt of dl-methionine, 0.1% Agrado (Novus International, Inc., St. Louis, MO), 
0.1% vitamin A/D/E.
2 The concentrate mix was comprised of (DM basis): 50.7% corn germ meal; 19.2% 
citrus pulp, 4.9% blood meal, 4.8% bakery product, 4.0% molasses, 4.2% calcium 
carbonate, 3.1% sodium bicarbonate, 2.2% salt, 2.0% dextrose, 1.9% urea, 1.4% 
Optigen II (Alltech, Lexington, KY), 0.6% magnesium oxide, 0.3% Alimet (88% 
aqueous solution of dl, 2-hydroxy-4-(methylthio) butanoic acid, Novus Internation-
al, Inc., St. Louis, MO), 0.3% selenium 0.06%, 0.2% trace minerals, 0.2% calcium 
salt of dl-methionine, 0.1% Agrado (Novus International, Inc., St. Louis, MO), 
0.1% vitamin A/D/E.
3 Prilled saturated FFA, MS Specialty Nutrition, Dundee, IL.
4 Values represent average of 3 weekly TMR samples composited into one sample 
for analysis.
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Services (Hagerstown, MD) for analysis using wet chemistry techniques for CP 
(AOAC, 2000), acid detergent insoluble CP [CP determined using AOAC (2000) after 
acid detergent extraction (AOAC, 2000)], neutral detergent insoluble CP [AOAC 
(2000) method for CP after neutral detergent extraction (Van Soest et al., 1991)], 
soluble CP, (Krishnamoorthy et al., 1982), ADF (AOAC, 2000), NDF (AOAC, 2000), 
lignin (Goering and Van Soest, 1970), starch (Hall, 2009), sugar (Dubois et al., 1956), 
ether extract (AOAC, 2000), and ash (AOAC, 2000). Chemical composition of the basal 
TMR based on the composition of the components is reported in Table 5-1. During the 
experiment, free choice water was available at all times.
During the fi rst period, two cows received subcutaneous insulin glargine (L) 
treatments of 0.15 IU/kg BW twice daily at 0900 and 2100 h, for a total daily dose 
of 0.3 IU/kg BW. The third cow served as a control in the fi rst period and received 
a 2-ml injection of sterile water. Treatments were reversed in the second period. 
On d 4 of each period, simultaneous blood samples were collected from intercostal 
arterial and abdominal subcutaneous mammary vein catheters at hourly intervals for 
12 h beginning at 0900 h and transferred into heparinzed glass tubes. Plasma was 
harvested by centrifugation (3,000 x g for 20 min at 4ºC) and plasma was harvested 
into three aliquots, quickly frozen with liquid N2, and then stored at -20ºC. An 
additional aliquot of plasma (0.65 ml) was added to ice-cold sulfosalicylic acid (5%) 
containing norleucine (2.5 μM) as an internal standard for amino acid analysis. The 
mixture of plasma and sulfosalicylic acid was vortexed extensively and kept on ice at 
40ºC overnight. The following day, after vortexing again, the plasma and sulfosalicylic 
acid mixture was centrifuged for 10 min at 4°C (15,800 x g). For each cow, the 
deproteinized plasma from the 12 hourly samples were composited at 2-h intervals 
to give six pairs of arterial and venous samples for each day within each period. 
Deproteinized plasma samples were frozen at -80ºC until analysis for AA by HPLC 
(Mackle et al., 1999a).
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To calculate uptake of amino acids and blood constituents by the mammary 
gland from AV differences, mammary blood fl ow was estimated using the Fick 
principle according to the method described by Cant et al (1993), which assumes that 
tissue uptake = AV difference x blood fl ow. Phenylalanine and tyrosine were used as 
the indicator compounds as both are transferred stoichiometrically from blood into 
milk protein (Mepham, 1982). Blood proteins were assumed to be 3.5% of the total 
milk protein and the following equation was used to calculate blood fl ow:
MBF = (FYB x 0.965)/FYA-V
  where:
     FYB = Phe + Tyr output in milk protein (moles per hour), and
     FYA-V = Phe + Tyr AV differences (moles per liter).
Cows were milked three times daily at 0700, 1500, and 2300 h and individual 
milk weights were recorded. On d 4 of each treatment period, milk samples were 
obtained at each milking and stored at 4°C with a preservative (2-bromo-2-nitro-1, 
3 propanediol) until analyzed (Dairy One Cooperative Inc., Ithaca, NY) fat, protein, 
lactose using midinfrared spectroscopy (AOAC, 2000; method 972.160), and SCC by an 
optical fl uorescent method (AOAC, 2000; method 978.26). A second aliquot of samples 
was collected and samples were composited by day in proportion to individual milk 
weights, representing d 3 and 4 of the treatment period. These composite samples were 
analyzed for milk N fractions. Casein was determined by the indirect method (Lynch 
et al., 1998) such that casein was precipitated at pH 4.6 in acetic acid and sodium 
acetate, and noncasein nitrogen (NCN) in the fi ltrate was measured by Kjeldahl N 
analysis. Total nitrogen (TN) of the sample was also measured by Kjeldahl analysis 
(Barbano et al., 1990). The amount of casein (N x 6.38) in the sample was calculated as 
the difference between the amount of TN and NCN. To determine NPN, proteins were 
precipitated and fi ltered from the sample by addition of 12% (wt.:vol.) trichloroacetic 
acid (Barbano et al., 1991). The N content of the fi ltrate, as measured by Kjeldahl N 
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analysis, is the NPN (N x 6.38) fraction. True protein can be calculated by difference 
taking the difference between TN and NPN (N x 6.38).
Plasma Hormone and Metabolite Analysis
Plasma concentrations of glucose were determined by enzymatic analysis 
(glucose oxidase) using a commercially-available reagents (#P7119 PGO Enzyme 
Preparation, #F5803 3,3’Dimethoxy benzidine dihydrochloride; Sigma Aldrich, St. 
Louis, MO). Intra-assay and interassay coeffi cients of variation (CV) for glucose 
analysis were 2.6 and 3.3%, respectively. Plasma urea nitrogen was measured by the 
hypochlorite-phenol nitroprusside method using a commercially available enzymes 
and reagents (#U3383 Urease Buffer Reagent, #P6994 Phenol Nitroprusside solution, 
#A1727 Alkaline Hypochlorite solution; Sigma Aldrich, St. Louis, MO). Intra-
assay and interassay coeffi cients of variation for PUN analysis were less than 4 and 
7%, respectively. Spectrophotometric readings were made using a Versamax tunable 
microplate reader (Molecular Devices, Sunnyvale, CA). Plasma insulin concentration 
was determined by a commercially available radioimmunoassay kit which 
has 90% cross-reactivity with native bovine insulin (#PI-12K Porcine Insulin 
Radioimmunoassay, LINCO Research, St. Charles, MO). Intra-assay and interassay 
CV for the RIA insulin analysis were both 10%. 
Statistical Analysis
Data were subjected to analysis of variance using the MIXED procedure of 
SAS (SAS Institute, 2001). Data presented here represent data collected on d 4 of 
the treatment period. The model included the fi xed effects of treatment, sequence of 
treatments, and the interaction of treatment x sequence. Signifi cance was declared 
at P < 0.10 and trends for 0.10 < P < 0.15. Least squares means are presented 
throughout.
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RESULTS AND DISCUSSION
Intake, Milk Production, and Milk Components
The ingredient and nutrient composition of the basal diet is presented in Table 
5-1. Dry matter intake averaged 25.7 kg/d and did not differ between treatments (Table 
5-2). Insulin, when given alone or in combination with glucose, has been reported to 
have mixed effects on intake in ruminants. Cows given regular insulin at a dose of 0.3 
U/kg BW (Schmidt, 1966) after each milking had decreased milk production during 
the treatment period and signs of hypoglycemia three days after the starting treatment. 
In early lactation, injection of slow release insulin tended exert a quadratic effect on 
in DMI, with the highest DMI occurring at a insulin dose of 0.14 IU/kg BW per day 
(Hayirli et al., 2002). In sheep, insulin effects on DMI were also variable (Deetz et al., 
1980), sometimes causing a decrease in intake while at other times having no effect on 
intake depending on dose or route of administration.
 The effects of treatment on milk yield and composition are reported in Table 
5-2. Milk yield tended to be 1.5 kg lower during the L treatment (P = 0.15). In a 10-d 
production study using L at a higher dose (0.2 IU/kg BW, twice daily) and discussed 
in Chapter 4, there was no effect of L on milk yield. Milk protein and fat contents and 
yields were not affected by treatment. Given the limited number of cows in the present 
study, differences in production variables were not expected but are reported here for 
reference in later discussion regarding amino acid uptake and utilization. While some 
studies have shown positive effects of insulin (through hyperinsulinemic-euglycemic 
clamps) on milk protein yield (McGuire et al., 1995; Griinari et al., 1997; Mackle et 
al., 1999b), others have shown no change in milk protein yield (Metcalf et al., 1991; 
Molento et al., 2002). The differences in milk protein yield in other studies may have 
been driven by a greater elevation in circulating insulin concentrations. In the present 
study and those by Metcalf et al. (1991) and Molento et al (2002), insulin concentrations 
were much lower than those from the hyperinsulinemic-euglycemic clamp studies of 
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McGuire et al. (1995), Griinari et al. (1997) and Mackle et al. (1999b; 2000) where 
insulin concentrations were 4 to 5-fold higher than baseline concentrations.
Lactose content and yield were both reduced by 2.1 and 5.1%, respectively, 
by twice-daily treatment with L. Studies using hyperinsulinemic-euglycemic clamps 
or insulin plus glucose infusions have also observed decreases in milk lactose 
concentrations and yields (Schmidt, 1966; Leonard and Block, 1997), whereas 
glucose infusions increase milk lactose concentrations (e.g. Leonard and Block, 
1997; Cant et al., 2002). Though glucose is the main substrate for lactose synthesis, 
it does not appear to be the only driver for lactose synthesis as studies using phlorizin 
to increase glucose disposal in the urine have shown no change in lactose synthesis 
in lactating dairy cows (Amaral-Phillips et al., 1993; Bradford and Allen, 2007), 
though plasma glucose concentrations in these studies were only reduced nominally 
despite large quantities of urinary glucose disposal. Work by Bradford and Allen 
(2005) in late lactation cows suggests that cows at this stage of lactation have 
suffi cient gluconeogenic capacity in the liver to overcome the phlorizin-induced 
glucose defi cit.
Table 5-2. Production responses to twice-daily subcutaneous injections of 
insulin glargine
Treatment1 P-value
Variable Control Insulin glargine SEM  Trt
DMI, kg/d 25.30 26.13 2.12 0.33
Milk, kg/d 47.16 45.64 4.34 0.15
Fat, % 3.64 3.76 0.36 0.31
Fat yield, kg/d 1.73 1.73 0.33 0.88
Protein, % 2.94 3.11 0.19 0.39
Protein yield, kg/d 1.39 1.42 0.22 0.74
Lactose, % 4.94 4.83 0.03 0.094
Lactose yield, kg/d 2.33 2.21 0.21 0.091
Total solids, % 12.42 12.58 0.57 0.18
Total solids yield, kg/d 5.88 5.76 0.80 0.37
SCC, cells/ml (x 1,000) 600 911 1160 0.67
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile water. During 
insulin glargine treatment, cows received twice-daily subcutaneous injections of insulin glargine (0.15 IU/kg 
BW), for a total daily dose of 0.30 IU/kg.
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Though SCC was not affected by treatment (P = 0.67), the average SCC was 
high and there was large variation in SCC due to the high somatic cell counts of one 
animal. During the fi rst period, one cow on the L treatment unexpectedly had a high 
SCC and this carried over to the second period, though the SCC was not as high as 
in the fi rst period for this animal. The effects of elevated SCC are relevant to the 
discussion of milk protein composition and interpretation of the protein composition 
results. Elevated SCC and subclinical mastitis are associated with reduced milk yield 
(Hagnestam-Nielsen et al., 2009) and may help explain the trend for reduced milk yield 
observed in this study. In another study where insulin was given without glucose, there 
was no change in milk production (Metcalf et al., 1991), suggesting insulin can be 
given by itself without severe hypoglycemia and losses in production.
Milk Nitrogen Fractions and Protein Composition
Results for milk N composition and fractions are reported in Table 5-3. The 
TP concentrations as determined by Kjeldahl analysis were similar to the results 
obtained from analysis by Dairy One laboratory (Table 5-2). Casein content and yield 
were not affected by treatment (P > 0.10) and casein expressed as a percent of true 
protein was also similar between the control and L treatments. Despite the limited 
replication in this study, NCN was 7.4% higher during the L treatment (P = 0.006). 
In a larger production study discussed in Chapter 4, treatment with L at a higher 
dose (0.2 IU/kg BW, twice daily) also increased the amount of NCN in milk protein, 
similar to that reported here. In that study, cows treated with L also had higher casein 
content and yield than control cows. Mackle et al. (1999b) also observed an increase in 
casein and NCN under conditions of elevated circulating insulin. Similarly, Molento 
and coworkers (2002) observed an increase in casein percent under a 60% increase in 
circulating insulin concentrations, though casein and protein yields themselves were 
not different in that study. The lack of a casein and overall true protein response in 
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the present study may be explained by the elevated SCC observed for one cow in this 
small-scale experiment, as high SCC can increase proteolysis of casein in raw milk 
(Verdi et al., 1987; Ma et al., 2000). 
Mammary Blood Flow
Estimated mammary blood fl ow was not affected by treatment with L (P = 
0.33). The least squares means for mammary blood fl ow were 725 and 627 mls blood/
ml milk (± 135) for the control and L treatments, respectively. On a per hour basis, 
estimated mammary blood fl ow was 1398 and 1172 L/hr (± 126.6) for the control 
and L treatment periods, respectively (P = 0.26). Treatment with insulin has been 
reported to have varied results on mammary blood fl ow in ruminants. Infusion of 
insulin into the external pudic artery, without glucose infusion, decreased blood fl ow 
by 30% in lactating cows (Metcalf et al., 1991). Hyperinsulinemic-euglycemic clamps 
appear to increase blood fl ow when compared to control animals (Mackle et al., 2000; 
Table 5-3. Composition of milk proteins as affected by twice-daily 
subcutaneous injections of insulin glargine in lactating dairy cows
Treatment1 P-value
Variable Control Insulin glargine SEM  Trt
Crude protein,2 % 3.12 3.27 0.19 0.38
True protein,3 % 2.93 3.08 0.19 0.37
Casein,4 % 2.38 2.47 0.12 0.51
Casein, kg/d 1.12 1.13 0.16 0.93
Casein, % of true protein 81.14 80.31 1.24 0.34
Whey,5 % 0.55 0.61 0.07 0.012
Whey, kg/d 0.26 0.28 0.06 0.015
NCN x 6.38, 6 % 0.74 0.79 0.07 0.006
NPN x 6.38, 6 % 0.19 0.19 0.00 0.49
Milk urea nitrogen,7 mg/dl 14.1 14.3 1.63 0.92
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile water. During 
insulin glargine treatment, cows received twice-daily subcutaneous injections of insulin glargine (0.15 IU/kg 
BW), for a total daily dose of 0.30 IU/kg.
2 Crude protein is equal to total nitrogen (TN) x 6.38.
3 True protein (TP) calculated as (TN - NPN) x 6.38.
4 Casein protein is calculated as (TN - NCN) x 6.38.
5 Whey protein calculated as (NCN - NPN) x 6.38.
6 Both NPN and NCN are multiplied by 6.38 to allow comparison with other protein fractions.
7 Milk urea nitrogen was measured using an infrared method.
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Bequette et al., 2001; Bequette et al., 2002). The disparity between an increase or 
decrease in blood fl ow appears to be dependent on co-infusion of glucose to maintain 
euglycemia. Bequette et al. (2001) used ultrasonic fl ow probes to measure mammary 
blood fl ow during hyperinsulinemia in goats and observed that when blood glucose 
concentrations fell below normal concentrations, blood fl ow was also lower and as 
euglycemia was eventually established through glucose infusion, blood fl ow increased 
to higher levels. Duodenal infusion of glucose at increasing doses caused linear 
increases in mammary blood fl ow coinciding with a linear increase in plasma glucose 
concentrations (Rulquin et al., 2004). However, close arterial infusion of glucose to the 
mammary gland blood supply resulted in a decrease in blood fl ow (Cant et al., 2002), 
suggesting that whole-body glucose metabolism may have different effects on blood 
fl ow than glucose supply available to the mammary gland.
Plasma Hormones and Metabolites
Results for plasma metabolite and hormone analysis are shown in Table 5-
4. As expected, both arterial and venous concentrations of plasma glucose were 
decreased by approximately 10% (P < 0.001) during the L treatment period. Glucose 
concentrations during the L treatment were still within normal physiological ranges for 
lactating dairy cows and arterial plasma concentrations averaged 63.1 and 56.9 mg/dl 
for the control and L treatments, respectively. The AV difference for glucose across 
the mammary gland was also lower during the L treatment period (P = 0.001) and 
when taking blood fl ow into account, mammary glucose uptake was reduced by 23% 
during the L treatment (P < 0.001). The AV differences observed in the present study 
were similar to those reported elsewhere (Metcalf et al., 1991; Mackle et al., 2000). 
However, under conditions of the hyperinsulinemic-euglycemic clamp, uptake of 
glucose across the mammary gland is commonly higher during the clamp (Mackle et 
al., 2000), perhaps due to the additional glucose, and thus energy supply, to the animal.
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In this study, it would be expected that the decrease in mammary glucose uptake 
is not related to direct effects of L on the mammary gland, per se. Glucose uptake in the 
mammary gland is independent of insulin as GLUT 1 acts in an insulin-independent 
manner. Other studies have shown no effect of insulin on glucose uptake in the 
mammary gland (Laarveld et al., 1981; Metcalf et al., 1991), suggesting that the changes 
in blood fl ow observed in the present study, though not statistically different, were the 
main explanatory variable for the reduction in glucose uptake during L treatment.
Arterial plasma urea nitrogen (PUN) did not differ by treatment (P > 0.10) 
and averaged slightly more than 14 mg/dl for both treatments. Though studies with 
hyperinsulinemic-euglycemic clamps have shown reduced PUN during clamp 
periods (Mackle et al., 1999b; Bequette et al., 2002), in these studies, there were also 
signifi cant increases in milk protein production by the mammary gland, suggesting 
increased utilization of nitrogen under those experimental conditions. As there was no 
change in either true milk protein or milk urea nitrogen in the present study, changes 
in PUN would not be expected given these observations.
Table 5-4. Effect of twice-daily subcutaneous injections of insulin glargine 
in lactating dairy cows on plasma concentrations of glucose, insulin, and 
urea nitrogen.
Treatment1 P-value
Variable Control Insulin glargine SEM  Trt
Glucose
Arterial, mg/dl 63.1 56.9 0.77 <0.001
Venous, mg/dl 45.4 40.7 0.54 <0.001
Arteriovenous difference, mg/dl 17.8 16.2 0.93 0.001
Extraction effi ciency, % 28.2 28.4 1.22 0.71
Uptake, g/h 247.7 190.6 10.39 <0.001
Plasma urea nitrogen
Arterial, mg/dl 10.4 10.3 1.06 0.81
Insulin
Arterial, ng/ml 0.89 1.20 0.11 0.009
Venous, ng/ml 0.85 1.21 0.12 0.002
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile water. During 
insulin glargine treatment, cows received twice-daily subcutaneous injections of insulin glargine (0.15 IU/kg 
BW), for a total daily dose of 0.30 IU/kg.
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Arterial and venous plasma insulin concentrations were about 30% higher 
during the L treatment period. Though these concentrations are nowhere near the 
400 to 500% elevation in hyperinsulinemic-euglycemic clamps (e.g. McGuire et al., 
1995; Griinari et al., 1997; Mackle et al., 1999b), given that glucose concentrations 
decreased by 10%, we were successfully able to increase insulin-like activity without 
the negative consequences of severe hypoglycemia observed in other studies when 
insulin alone was infused (Kronfeld et al., 1963; Schmidt, 1966). Molento et al. (2002) 
used a hyperinsulinemic-euglycemic clamp in high producing cows (49 kg/d milk 
production), and elevated circulating insulin concentrations only 60% above the saline 
infusion comparison. In the study by Molento et al. (2002), there was also no effect of 
insulin on protein yield, perhaps suggesting that greater elevation of insulin-activity 
is needed to stimulate greater milk protein synthesis in the mammary gland. It 
should be noted, however, that measurement of actual insulin activity in cows treated 
with insulin glargine has been diffi cult, which has been discussed in more detail in 
Chapter 3. Therefore, changes in glucose concentrations serve as a limited proxy for 
overall insulin activity.
Amino Acid Utilization
Arterial concentrations of amino acids are presented in Table 5-5 and were 
generally not different between the control and L treatments. Plasma Gly (P = 0.096) 
and Ser (P = 0.075) concentrations were higher during treatment with L, but no other 
arterial concentrations of individual amino acids were affected by treatment. Arterial 
concentrations of nonessential amino acids tended to increase during the L treatment 
period (P = 0.15). 
Plasma amino acid AV differences are presented in Table 5-6. For the essential 
amino acids, treatment with L decreased the AV difference of Arg (P = 0.011) and 
there was a tendency for a decrease in the AV difference for Val (P = 0.101), though 
105
these differences are quite small numerically. Treatment with L increased or tended to 
increase the AV differences for Cys (P = 0.031), Lys (P = 0.145), Phe (P = 0.089), and 
Trp (P = 0.099). Of the nonessential amino acids, the AV differences were higher for 
Asn (P = 0.050) and Cit (P = 0.027) during the L treatment. The AV difference for Glu 
was lower (P = 0.043) during L treatment.
When the amino acids were aggregated into either essential, non-essential, 
branched-chain, glucogenic or total amino acid groups (Table 5-7), essential and 
nonessential amino acid uptake by the mammary gland was reduced by twice-
Table 5-5. Effect of twice-daily subcutaneous injections of insulin 
glargine in lactating dairy cows on arterial concentrations (μM) 
of AA
Treatment1 P-value
Variable Control Insulin glargine SEM Trt
Essential AA
Arg 55.4 54.7 7.33 0.76
Cys 16.9 17.4 0.83 0.30
His 35.6 36.7 3.68 0.59
Ile 78.0 73.4 4.23 0.58
Leu 139.6 126.5 6.76 0.24
Lys 63.0 62.8 3.92 0.93
Met 18.9 20.7 2.29 0.31
Phe 39.5 40.6 0.93 0.57
Thr 71.4 75.0 9.15 0.56
Trp 22.5 22.6 2.51 0.93
Val 240.7 230.0 10.65 0.61
Nonessential AA
Ala 171.0 173.5 18.39 0.70
Asn 42.1 50.3 13.27 0.28
Asp 8.6 9.1 0.78 0.74
Cit 70.1 71.0 7.13 0.80
Gln 149.2 160.1 4.63 0.35
Glu 35.2 34.0 2.09 0.58
Gly 239.6 265.2 41.31 0.096
Orn 32.5 30.7 5.75 0.74
Pro 64.1 73.9 7.06 0.20
Ser 71.0 80.1 7.10 0.075
Tyr 46.0 45.7 4.97  0.95
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile 
water. During insulin glargine treatment, cows received twice-daily subcutaneous injections of 
insulin glargine (0.15 IU/kg BW), for a total daily dose of 0.30 IU/kg.
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daily injections of L (P = 0.059 and P = 0.086, for essential and nonessential AA, 
respectively). Uptake of essential amino acids was reduced 16.3% by treatment with 
L, and 60.1% of the decrease in essential amino acids can be accounted for by the 
reduction in uptake of the branched-chain amino acids. Uptake of the branched-chain 
amino acids was reduced 19.7% by treatment with L (P = 0.031). Metcalf et al. (1991) 
also observed a decrease in the uptake of amino acids when insulin was infused into 
the external pudic artery. The insulin glargine treatment tended to reduce uptake of 
the glucogenic amino acids (P = 0.10), and the uptake to output ratio for the glucogenic 
Table 5-6. Effect of twice-daily subcutaneous injections of insulin 
glargine in lactating dairy cows on arteriovenous concentrations 
differences (μM) of AA
Treatment1 P-value
Variable Control Insulin glargine SEM Trt
Essential AA
Arg 30.0 29.2 3.97 0.011
Cys 1.0 1.4 0.19 0.031
His 9.4 9.3 1.24 0.84
Ile 30.2 29.8 2.78 0.18
Leu 52.3 47.0 4.40 0.55
Lys 37.8 39.5 4.05 0.15
Met 9.3 9.4 1.48 0.23
Phe 13.8 15.9 2.19 0.089
Thr 21.2 21.1 2.82 0.94
Trp 1.0 2.3 0.26 0.099
Val 40.9 40.2 3.49 0.101
Nonessential AA
Ala 37.6 32.3 6.70 0.18
Asn 8.9 14.4 6.62 0.050
Asp 2.4 2.5 0.13 0.67
Cit 4.6 8.0 0.61 0.027
Gln 34.6 36.8 3.50 0.22
Glu 25.7 23.6 1.96 0.043
Gly 1.2 0.3 1.75 0.25
Orn 16.6 15.5 3.72 0.71
Pro 12.2 13.6 1.71 0.64
Ser 22.2 21.9 6.78 0.80
Tyr 14.7 14.8 2.03  0.88
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile 
water. During insulin glargine treatment, cows received twice-daily subcutaneous injections of 
insulin glargine (0.15 IU/kg BW), for a total daily dose of 0.30 IU/kg.
107
Table 5-7. Effect of twice-daily subcutaneous injections of insulin 
glargine in lactating dairy cows on mammary amino acid utilization
Treatment1 P-value
Variable Control Insulin glargine SEM Trt
Essential AA2
Arterial, μM 781 760 32.9 0.73
Venous, μM 535 515 28.4 0.71
AV difference, μM 247 245 24.0 0.89
Extraction effi ciency, % 31.6 32.2 2.77 0.88
Uptake, mM/hr 344.0 287.8 3.67 0.059
Output, mM/hr 255.6 235.0 13.25 0.29
Uptake:output ratio 1.34 1.23 0.061 0.16
Nonessential AA3
Arterial, μM 929 993 103.6 0.21
Venous, μM 749 810 73.4 0.26
AV difference, μM 180 184 33.5 0.52
Extraction effi ciency, % 19.2 18.4 1.61 0.54
Uptake, mM/hr 249.9 214.6 21.98 0.086
Output, mM/hr 300.7 275.6 15.29 0.24
Uptake:output ratio 0.83 0.78 0.039 0.13
Branched-chain AA
Arterial, μM 458 430 18.0 0.46
Venous, μM 335 313 25.1 0.65
AV difference, μM 123 117 8.5 0.58
Extraction effi ciency, % 27.1 27.2 2.95 0.97
Uptake, mM/hr 171.7 137.9 4.23 0.031
Output, mM/hr 118.0 108.5 6.13 0.29
Uptake:output ratio 1.45 1.28 0.113  0.17
Glucogenic AA4
Arterial, μM 1020 1085 117.3 0.24
Venous, μM 801 863 79.3 0.28
AV difference, μM 220 222 38.7 0.64
Extraction effi ciency, % 21.4 20.4 1.58 0.49
Uptake, mM/hr 304.8 259.8 24.30 0.10
Output, mM/hr 325.1 299.0 16.57 0.25
Uptake:output ratio 0.93 0.87 0.035 0.052
Total AA
Arterial, μM 1710 1754 133.4 0.65
Venous, μM 1284 1325 82.9 0.70
AV difference, μM 427 429 57.3 0.93
Extraction effi ciency, % 24.9 24.4 1.84 0.84
Uptake, mM/hr 594.0 502.4 24.35 0.077
Output, mM/hr 556.3 510.5 28.54 0.26
Uptake:output ratio 1.06 0.99 0.011 0.13
1During control treatment, cows received twice-daily subcutaneous injections of 2 ml of sterile water. 
During insulin glargine treatment, cows received twice-daily subcutaneous injections of insulin glargine 
(0.15 IU/kg BW), for a total daily dose of 0.30 IU/kg.
2Essential AA include: Arg, Cys, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, and Val.
3Nonessential AA include: Ala, Asn, Asp, Gln, Glu, Gly, Pro, Ser, Orn, Cit, and Tyr.
4Glucogenic AA include all NEAA plus Arg and His.
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amino acids was also reduced by treatment with L (P = 0.052). Recall, however, that 
milk protein yield was not different between treatments (Table 5-2 and Table 5-3). 
The observation that the mammary gland had reduced total amino acid uptake (P = 
0.077) yet maintained similar milk protein yield suggests mammary gland utilization 
of amino acids was altered by treatment with L. Though the total uptake to output of 
total amino acids was nearly balanced for both treatments, there was a tendency for a 
difference in the uptake to output ratios (P = 0.13, Table 5-7) with the ratio being 1.06 
during the conrol treatment and 0.99 during treatment with L. The amino acid balance 
across the mammary gland is similar to cows subjected to the hyperinsulinemic-
euglycemic clamp (Mackle et al., 2000) and generally the amount of amino acid N 
taken up by the mammary gland can be accounted for in milk protein (Mepham 
Figure 5-1. Effects of twice-daily subcutaneous injections of insulin glargine on 
mammary uptake of essential and nonessential AA (mM/hr). Data presented are 
least square means (± standard error) for essential (white bars) and non-essential 
(black bars) amino acids. Cows received either 2 ml of sterile water or 0.15 IU insulin 
glargine/kg BW twice daily by subcutaneous injection during the treatment periods. 
Essential and nonessential amino acid uptake by the mammary gland was reduced by 
insulin glargine treatment (P = 0.059 and P = 0.086, for essential and nonessential 
AA, respectively).
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and Linzell, 1966). In lactating goats, Bequette et al., (2001) also observed reduced 
mammary uptake of plasma AA under a hyperinsulinemic-euglycemic clamp. In that 
study the authors suggested that insulin may reduce catabolism of amino acids in the 
mammary gland, thereby sparing them for milk protein synthesis.
CONCLUSIONS
Though no overall change in either milk protein content or yield was observed 
in the present study, data from this study suggest that L alters uptake and utilization 
effi ciency of amino acids in the mammary gland. Based on the research reported here 
and elsewhere, it appears the effects of insulin on amino acid uptake and use by the 
mammary gland differs by how much insulin is elevated in the cow and by whether 
glucose is also infused during insulin infusion or treatment.
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CHAPTER SIX: INTEGRATED SUMMARY AND CONCLUSIONS 
Most research related to improving milk protein production in lactating dairy 
cows has focused on determining and meeting the amino acid needs of the cow and 
using dietary approaches to maximize N effi ciency. Despite large improvements in our 
understanding of the cow’s nutrient requirements for optimal milk production, there is 
still a gap in the knowledge surrounding milk protein synthesis. Rather than looking at 
milk protein synthesis from a dietary point of view and thinking of amino acids purely 
as substrates for protein synthesis, employing alternative approaches focused on 
factors affecting the regulation of milk protein synthesis in the mammary gland have 
had impressive responses. Alteration of metabolism and hormone concentrations in 
lactating cows has produced more signifi cant improvements in milk protein yield than 
dietary approaches. Evidence from hyperinsulinemic-euglycemic clamp studies where 
milk protein output has increased by up to 28% (Griinari et al., 1997) suggests that 
there is opportunity for improving milk protein production in the modern dairy cow 
beyond current management conditions. 
Though hyperinsulinemic-euglycemic clamps are useful in an experimental 
context, the practical application of these studies has not fully been explored. 
Additionally, during hyperinsulinemic-euglycemic clamps, although insulin is credited 
as the source of any changes in production or metabolism that occur, signifi cant 
amounts of glucose, and thus energy, are being infused into the cow. In the study by 
Mackle (1999), the amount of glucose infused per day (3.336 kg) was the equivalent 
of 12.2 Mcal NEL/d (Leonard and Block, 1997), which is a considerable amount of 
energy. Additionally, intravenous (Amaral et al., 1990) and duodenal (Rulquin et al., 
2004) glucose infusions have been shown to increase milk protein yield, so the effects 
of glucose and insulin are confounded. It would be ideal to evaluate the effects of 
insulin without concurrent glucose infusion. However, when insulin is administered 
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alone, a confounding effect of hypoglycemia is also present (Kronfeld et al., 1963; 
Schmidt, 1966) making research on the effects of insulin a challenge.
Numerous insulins and insulin analogues are available in human medicine for 
a variety of uses and needs, including insulin products that have extended duration 
of action and release into the body of the subject. The potential to use slow-release 
insulin products from human medicine in lactating dairy cows offers opportunity to 
study the effects of insulin without the need to provide glucose to maintain normal 
glycemic state.
For this doctoral research, two insulin sources from human medicine were 
selected based on their prior use in dairy cows (Humulin-N or H; Hayirli et al., 2002) 
and pharmacokinetic and pharmacodynamic properties (insulin glargine or L). To 
test the effects of these two forms of slow-release insulin on the metabolism and 
production of lactating dairy cows, three experiments were carried out and included a 
dose-response study, a production trial, and a mammary metabolism study.
In Chapter 3, both slow-release insulin sources were used in a dose-
response study to evaluate the effects of both insulin types on lactating dairy cow 
plasma profi les of insulin and glucose. In separate experiments, cows were given 
a single subcutaneous injection of either H or L at doses of 0, 0.1, 0.2, or 0.4 
IU/kg BW. Increasing doses of both H and L caused linear decreases in plasma 
glucose concentrations in lactating dairy cows over a 24-h period. Plasma insulin 
concentrations increased with increasing dose of H. Though a standard assay to 
measure L and its metabolites in plasma is not available, it was evident by the 
changes in plasma glucose that L exerted insulin-like effects in dairy cows. There 
were no changes in dry matter intake (DMI) on the day of the injection and sampling, 
suggesting that critical thresholds for hypoglycemia were not reached with the doses 
given. However, the highest doses of H and L caused plasma glucose decrease to 
20 mg/dl in some cows, which is certainly below normal thresholds for euglycemia 
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in dairy cows. The objective of the overall research was to determine a dose of 
both forms of insulin that could be used to study the effects of insulin without large 
decreases in glycemia. Therefore, it was decided not to use the highest dose of either 
insulin in a once-daily injection. Based on the 24-h profi les of glucose following H 
and L insulin injection, it was decided to proceed with intermediate doses (0.15 and 
0.2 IU/kg), given twice daily in further experiments.
In Chapter 4, both types of slow-release insulin were used in a study to 
determine their effects on milk production. Cows were blocked into two groups and 
within each group randomly assigned to control (C), H, or L treatments. The slow-
release insulins were given twice daily at 12-h intervals via subcutaneous injection 
at a dose rate of 0.2 IU/kg BW, for a total daily dose of 0.4 IU/kg BW. There were no 
effects of treatment on DMI or overall milk yield. Protein and fat content increased 
by treatment with both H and L, but the overall yields of fat and protein were only 
increased by treatment with L. Lactose content decreased for cows treated with H 
and L, but lactose yield was only lower for L. Milk urea nitrogen concentrations were 
decreased by treatment with H and L. The conversion effi ciency of the predicted 
MP supply into milk protein observed here suggest that insulin may be altering the 
N economy of the cow and whole-body metabolism. As expected, plasma glucose 
concentrations were lower for cows treated with both slow-release insulin products, 
but the glucose concentrations were still within normal physiological ranges for 
lactating dairy cows. To explain some of the milk component responses observed here, 
proteins from mammary biopsies taken at the end of the experiment were analyzed 
for signaling proteins related to the mammalian target of rapamycin (mTOR) signaling 
cascade, which is involved with global protein synthesis. The ratio of phosphorylated 
Akt to total Akt differed by treatment was greatest for H. However, ratio of 
phosphorylated rpS6 to total rpS6 was not different among treatments. Though there 
was no difference in the downstream signal of mTOR (rpS6) in the mammary proteins, 
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the timing of the mammary biopsy may have affected the ability to detect differences 
in these treatments. Further work will need to be carried out to fully elucidate the 
cellular signaling by which H and L stimulate milk protein and fat synthesis in high 
producing cows.
In Chapter 5, a mammary metabolism study was carried out to evaluate the 
effect of L on amino acid uptake and use by the mammary gland. During the 4-d 
treatment period, cows were given 0.15 IU/kg BW of L, twice daily at 12-h intervals, 
for a total daily dose of 0.3 IU/kg BW. Simultaneous blood samples taken from the 
intercostal artery and subcutaneous abdominal vein allowed measurement of mammary 
clearance of amino acids and plasma metabolites. Though milk yield tended to be 
decreased by L in that study, subclinical mastitis may have been the causative agent 
explaining that observation. Regardless, milk protein yield was not different, despite 
the tendency to have lower total milk yield. Uptake of the essential and nonessential 
amino acids was reduced during treatment with L. The ability of the mammary gland 
to produce the same amount of milk protein with fewer substrates (amino acids), 
suggests slightly altered mammary metabolism during treatment with L.
Based on the research presented in this dissertation, it is apparent that 
insulin affects mammary metabolism and milk component synthesis. This research 
has shown that the effects of insulin can be studied in dairy cows without glucose 
infusion through use of slow-release insulin products used in human medicine. 
Additionally, this research supports the data from the hyperinsulinemic-euglycemic 
clamp studies (Griinari et al., 1997; Mackle et al., 1999), where impressive increases 
in milk protein production were observed. Though the increases in protein yield 
reported in Chapter 4 were much less than those observed in the clamp studies, 
particularly the clamp studies with supplemental amino acid or casein infusions, this 
research further defi nes the role of insulin in milk component production, without 
the confounding effect of glucose infusion. This research also supports the role for 
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insulin in changing mammary metabolism and utilization of amino acids, increasing 
the effi ciency of use of amino acids within the gland. Though the molecular 
mechanisms explaining these observations were not discernable from the mammary 
biopsies taken 12 to 16 h after the last insulin injection in the production study, 
mTOR signaling is still strongly hypothesized to be the signaling cascade induced by 
the insulin treatments described herein. The next steps for this line of research may 
include further defi ning the molecular mechanism by which H and L alter mammary 
metabolism to increase milk component production, evaluating longer-term effects 
of administration of H or L in dairy cows, looking at effects of H and L over 
various stages of lactation in lactating cows, and exploring dietary strategies to alter 
endogenous insulin production by the cow. 
The potential to make adjustments in diet to alter endogenous insulin secretion 
have been demonstrated previously in cows. Low forage to concentrate ratios in diets 
can increase insulin release in dairy cows (Jenny and Polan, 1975). In early lactation 
cows, plasma insulin concentrations were 52 and 41% higher on an insulinogenic 
diet for cows of high and low genetic merit than counterparts fed a control diet 
(Gong et al., 2002). In another early lactation study, cows fed a high starch diet had 
linear increase in plasma insulin concentrations when starch replaced fat in the diet 
(Garnsworthy et al., 2008). In the study by Garnsworthy et al., (2008) there were no 
differences among body condition scores during the 70 d experiment. Based on these 
observations, endogenous insulin secretion can be altered in dairy cows with changes 
in diet. However, the more important questions are: to what extent can endogenous 
insulin synthesis be increased to gain the potential benefi ts of improved milk protein 
production, and what are other potential consequences of altering a cow’s insulin 
production by dietary manipulation over the long term?
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APPENDIX
The images below are the scans obtained from developed fi lm from Western 
blot analysis described in Chapter 4 for phosphorylated ratios of Akt and rpS6. The 
lanes are labeled with the cow number and treatment and this orientation is the same 
for all blots.
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